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7ABSTRACT
In humans with a loss of uricase the final oxidation product of purine catabolism is
uric acid (UA). The prevalence of hyperuricemia has been increasing around the world
accompanied by a rapid increase in obesity and diabetes. Since hyperuricemia was first
described as being associated with hyperglycemia and hypertension by Kylin in 1923,
there has been a growing interest in the association between elevated UA and other
metabolic abnormalities of hyperglycemia, abdominal obesity, dyslipidemia, and
hypertension. The direction of causality between hyperuricemia and metabolic
disorders, however, is unceartain. The association of UA with metabolic abnormalities
still needs to be delineated in population samples.
Our overall aims were to study the prevalence of hyperuricemia and the metabolic
factors clustering with hyperuricemia, to explore the dynamical changes in blood UA
levels with the deterioration in glucose metabolism and to estimate the predictive
capability of UA in the development of diabetes.
Four population-based surveys for diabetes and other non-communicable diseases
were conducted in 1987, 1992, and 1998 in Mauritius, and in 2001-2002 in Qingdao,
China. The Qingdao study comprised 1 288 Chinese men and 2 344 women between
20-74, and the Mauritius study consisted of 3 784 Mauritian Indian and Mauritian
Creole men and 4 442 women between 25-74. In Mauritius, re-exams were made in
1992 and/or 1998 for 1 941 men (1 409 Indians and 532 Creoles) and 2 318
non-pregnant women (1 645 Indians and 673 Creoles), free of diabetes, cardiovascular
diseases, and gout at baseline examinations in 1987 or 1992, using the same study
protocol. The questionnaire was designed to collect demographic details, physical
examinations and standard 75g oral glucose tolerance tests were performed in all
cohorts. Fasting blood UA and lipid profiles were also determined.
The age-standardized prevalence in Chinese living in Qingdao was 25.3% for
hyperuricemia (defined as fasting serum UA > 420 ?mol/l in men and > 360 ?mol/l in
women) and 0.36% for gout in adults between 20-74. Hyperuricemia was more
prevalent in men than in women. One standard deviation increase in UA concentration
was associated with the clustering of metabolic risk factors for both men and women in
three ethnic groups. Waist circumference, body mass index, and serum triglycerides
appeared to be independently associated with hyperuricemia in both sexes and in all
ethnic groups except in Chinese women, in whom triglycerides, high-density
lipoprotein cholesterol, and total cholesterol were associated with hyperuricemia.
Serum UA increased with increasing fasting plasma glucose levels up to a value of
7.0-mmol/l, but significantly decreased thereafter in mainland Chinese. An inverse
relationship occurred between 2-h plasma glucose and serum UA when 2-h plasma
glucose higher than 8.0 mmol/l. In the prospective study in Mauritius, 337 (17.4%)
men and 379 (16.4%) women developed diabetes during the follow-up. Elevated UA
levels at baseline increased 1.14-fold in risk of incident diabetes in Indian men and
1.37-fold in Creole men, but no significant risk was observed in women.
In conclusion, the prevalence of hyperuricemia was high in Chinese in Qingdao, blood
UA  was  associated  with  the  clustering  of  metabolic  risk  factors  in  Mauritian  Indian,
Mauritian Creole, and Chinese living in Qingdao, and a high baseline UA level
8independently predicted the development of diabetes in Mauritian men. The clinical
use of UA as a marker of hyperglycemia and other metabolic disorders needs to be
further studied.
Keywords: Uric acid, Hyperuricemia, Risk factors, Type 2 Diabetes, Incidence,
Mauritius, Chinese
91 INTRODUCTION
As an end product of the purine metabolism in humans, the serum uric acid (UA)
concentration is determined by an interaction of genetic and environmental factors.
The UA levels are higher in humans and the Great and Lesser Apes due to parallel
mutations of the uricase gene that occurred during the mid Miocene era (Wu et al.
1992). The consequence of the mutation is that humans not only have higher UA levels
than most other mammals but they can not regulate UA levels as effectively as others
either (Johnson et al. 2004; Johnson et al. 2005b).
The uricase mutation may have conferred a survival advantage by helping to maintain
blood pressure (BP), stimulate salt-sensitivity, and induce insulin resistance (IR) and
mild obesity, thereby helping promote survival during a period of famine or stress
(Johnson et al. 2008). Western lifestyle, however, including western diet and physical
inactivity have swept the world during the past few decades. Since the current western
diet is high in meat and fructose, both which generate UA, humans today have higher
UA levels (range 238–595 ?mol/l) compared with primates that lack uricase (whose
UA levels are typically in the 178–238 ?mol/l range) (Johnson et al. 2005b).
Hyperuricemia  is  defined  as  a  serum  UA  concentration  in  excess  of  urate  solubility,
which is about 420 ?mol/l in men and 360 ?mol/l in women (Fang et al. 2000). People
with elevated UA, but without the symptoms of gout, nephropathy, or kidney stones
are classified as having asymptomatic hyperuricemia. If the gouty symptom does not
occur, people with asymptomatic hyperuricemia are usually unaware of their condition
and the possible consequences such as hypertension, diabetes, renal disease, and
cardiovascular diseases.
Increased urbanization, westernization, and economic development have already
contributed  to  a  worldwide  substantial  rise  in  obesity  and  diabetes.  Interestingly,  the
prevalence of hyperuricemia has shown a rise in both developing and developed
countries, accompanied by a rapid increased rate in obesity and diabetes (Chang et al.
2001; Conen et al. 2004; Darmawan et al. 1992). The prevalence of hyperuricemia and
gout has reportedly been increasing recently in large Chinese cities, even though it was
once considered to be rare in China (Chen et al. 1998; Fang et al. 1983; Li et al. 1997).
To our knowledge this is the first study on the prevalence of hyperuricemia and gout in
Qingdao, one of the largest harbor cities in China, with a high consumption rate of
seafood and beer.
Since hyperuricemia was first described as being associated with hyperglycemia and
hypertension by Kylin in 1923 (Kylin 1923), there has been a growing interest in the
association between elevated UA and other metabolic abnormalities of hyperglycemia,
abdominal obesity, dyslipidemia, and hypertension, as well as a continuing debating on
hyperuricemia as an additional component of the metabolic syndrome (Liou et al.
2006; Zavaroni et al. 1993). Serum UA is positively associated with plasma glucose in
healthy subjects (Facchini et al. 1991; Modan et al. 1987). This association, however,
is not consistent between healthy and diabetic individuals (Nakanishi et al. 2003;
Taniguchi et al. 2001; Tuomilehto et al. 1988). Since most individuals experience a
phase of impaired glucose tolerance (IGT) before progression to diabetes, it is unclear
to what extent serum UA independently predicts the development of diabetes during
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the pre-diabetes period. Hyperuricemia is associated with BP in middle-aged men
without diabetes, glucose intolerance, and the metabolic syndrome (Krishnan et al.
2007). Elevated UA is significantly associated with several indices of coronary heart
disease risk and a number of the metabolic abnormalities (Coutinho et al. 2007;
Ishizaka et al. 2005). Other studies, however, provided conflicting results in general
populations (Baker et al. 2005; Culleton et al. 1999; Wheeler et al. 2005).
Hyperuricemia occurs with increased frequency in several important metabolic
disorders in which no clear or direct cause–and-effect relationship in either direction
has been established. The association of UA with metabolic abnormalities still needs to
be delineated in other population samples.
The prevalence of obesity, hypertension, diabetes, dyslipidemia, and hyperuricemia
have been increasing over the last few decades in the southern Indian Ocean island of
Mauritius and in China due to rising living standards occurring with modernization and
urbanization (DECODE Study Group 2003; Dong et al. 2005; Li et al. 1997; Soderberg
et al. 2005). Population-based surveys with focus on diabetes were conducted in
Mauritius in 1987, 1992, and 1998 (Soderberg et al. 2004), and in Qingdao, China in
2001-2002. These data create a unique opportunity for description of the prevalence of
hyperuricemia and gout, evaluation of the association of UA levels with glucose
concentrations, estimation of the associations between serum UA and metabolic
abnormalities in the different ethnic groups from these two countries, and exploration
of the predictive value of UA for incident type 2 diabetes.
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2 REVIEW OF THE LITERATURE
2.1 UA
2.1.1 Physiology of UA
UA is an end product of purine metabolism and is related to the purine bases of the
nucleic  acids  in  humans.  Nearly  15  million  years  ago,  one  of  our  hominid  ancestors
acquired a mutation in the gene for uricase, the hepatic enzyme that degrades UA into
allantoin. As a consequence, having lost the ability to express urate oxidase, humans
are exposed to higher serum UA levels than other mammals (Marangella 2005; Wu
et al. 1992) with UA levels in the 59-119 ?mol/l range. The serum UA level is
determined by the balance between purine intake and UA production on the one hand
and UA elimination by renal and extrarenal routes on the other. Approximately two
thirds of total body urate are produced endogenously, the remaining one third is
accounted for by dietary purines. Approximately 70% of the urate produced daily,
however, is excreted by the kidneys. The rest is eliminated by the intestines. Normal
serum UA levels are less than 420 ?mol/l in men and 330-360 ?mol/l in women
(Johnson et al. 1999). UA levels are lower in premenopausal women because estrogen
is uricosuric (Nicholls et al. 1973). After menopause, UA levels in women are similar
to men. They also increase with age (Glynn et al. 1983). Furthermore, UA levels may
vary in the same individual by as much as 59 to 119 ?mol/l during the course of a day,
due to the effects of diet and exercise.
Hyperuricemia is arbitrarily defined as a serum UA concentration in excess of urate
solubility, which is about 420 ?mol/l in men and 360 ?mol/l in women. Hyperuricemia
may occur from excessive production of urate (overproduction) or decreased
elimination (underexcretion), and frequently a combination of both processes occur in
the same patient. Long-term hyperuricemia is a causal factor to damage development
in the joints, connective tissues, and kidney. Those with elevated UA levels, but
without gout, nephropathy or kidney stone symptoms, are classified as having
asymptomatic hyperuricemia.
Gout management is well identified. It includes rapid and safe termination of the acute
attacks of gouty arthritis, protection against further attacks prior to and during urate
lowering, and establishment and long-term maintenance of subsaturating serum UA
levels that will eventually normalize the extracellular urate pool. Nevertheless so far it
has not been determined whether the urate-lowering therapy suits asymptomatic
hyperuricemia. Allopurinol is arguably the most effective urate-lowering agent
available today and is generally well tolerated. About 2% of those individuals
receiving allopurinol develop hypersensitivity reactions, however, and 20% of those
are severe. Severe reactions include severe rash, toxic epidermal necrolysis, hepatitis,
interstitial nephritis, and death (Wortmann 2002). Recently, additional urate-lowering
agents have been developed and are currently undergoing clinical trials. These include
febuxostat, a xanthine oxidase inhibitor, structurally distinct from allopurinol and
metabolized mainly in the liver (Becker et al. 2004) and pegloticase (pegylated
recombinant porcine uricases), biological agents that replace the activity of uricase
(Sundy et al. 2007). The safety of these agents, however, is under evaluation.
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The rise in UA concentration has historically been viewed as simply a potential risk
factor for inducing gout, however, clinical gout is only the tip of the iceberg. If the
gouty symptom does not occur, people with asymptomatic hyperuricemia are usually
unaware of their condition. Hyperuricemia is associated with, and may predispose to,
hypertension, diabetes, renal disease, and cardiovascular disease.
Table 1 Prevalence (%) of hyperuricemia in different ethnic groups and geographic regions
Ethnicity Survey year Geographic locations Age Number Prevalence (%) Reference
(years) men/women men women
Caucasian 1970 Birminham, Winfrish and Glasgow,
UK
Adult 849/254 7.2 0.4 a (Sturge et al. 1977)
Caucasian 1989 Southern Germany 28.6 b 2.6 b (Gresser et al. 1990)
Caucasian 1990-1992 New Zealand ?19 139/176 9.4 10.5 (Klemp et al. 1997)
Chinese 1980
Beijing, Shanghai and Guangzhou,
China
?20 267/235 1.4 1.3 (Fang et al. 1983)
Chinese 1987-1988 Beijing urban area, China 40-58 1 062/951 15.4 11.0 (Li et al. 1997)
Beijing rural area, China 40-58 558/949 11.3 8.4 (Li et al. 1997)
Chinese 1995-1996 Littoral area, Shandong, China ?20 - 5.8 0.05 (Jiang et al. 1999)
Chinese 1998 Shanghai, China ?15 913/1 124 14.2 7.1 (Chen et al. 1998)
Chinese 2004-2006 Hangzhou, China Adult 1 468/906 19.1 3.4 (Chen et al. 2007)
Chinese (Han and
Muslim)
2006 Beijing, China Adult 1 217/780 13.8  6.0 (Fang et al. 2006)
Chinese, Han 1991-1992 Taiwan Kin-Hu, Kinmen ?30 1 515/1 670 25.8 15.0 (Lin et al. 2000)
Chinese, Han 1993-1996 Taiwan ?19 1 348/1 498 42.1 27.4 (Chang et al. 2001)
26.1b 17.0 b (Chang et al. 2001)
Taiwanese 1993-1996 Taiwan Metropolitan cities ?19 204/201 48.0 20.7 (Chang et al. 2001)
Taiwanese 1993-1996 Taiwan Mountainous area ?19 206/233 82.0 64.3 (Chang et al. 2001)
Taiwan aborigines 1990 Taiwan Mountainous area ?18 145/197 53.8 30.7 (Chou et al. 1998)
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Table 1 Continues
Ethnicity Survey year Geographic locations Age Number Prevalence (%) Reference
(years) men/women men women
Taiwan aborigines 1994-1999 Taiwan 12-15 476/464 50.4 37.7 (Ko et al. 2002)
Chinese and
Taiwan aborigines
1999-2000 Taiwan ?65 1 225/1 167 46.0 26.0 (Lee et al. 2005)
Thailander 1999-2000 Bangkok, Thailand ?15 376/1 005 18.4 7.8 (Lohsoonthorn et al. 2006)
Melanesian 1980 Fiji ?20 643/697 26.7 27.1 (Tuomilehto et al. 1988)
Asian Indian 1980 Fiji ?20 598/700 21.7 10.9 (Tuomilehto et al. 1988)
Maori 1963 New Zealand ?15 388/378 49.0 42.0 (Brauer et al. 1978)
Maori 1990-1992 New Zealand ?19 130/212 27.1 26.6 (Klemp et al. 1997)
Micronesian-
Polynesian
1978 Urban area in Nauru ?20 217/238 63.6 60.0 (Zimmet et al. 1978)
Malayo-Polynesian 1992 Rural area in Java Total: 4 683 24.3 12.2 (Darmawan et al. 1992)
African descent 1994 Seychelles 25-64 482/529 35.2 8.7 (Conen et al. 2004)
Arab 1998-1999 Saudi Arabia ?14 250/237 8.0 8.9 (Al-Arfaj 2001)
Parkateje Indian 1997 Amazon region, Brazil ?20 56/34 5.6 - (Tavares et al. 2003)
Japanese 2000 Okinawa, Japan 18-89 2 927/1 562 32.6 9.0 (Nagahama et al. 2004a)
White and African-
American
1987-1989 4 community, US 45-64 Total:14 481 11.2 c (Schmidt et al. 1996)
a Hyperuricemia defined as UA >420 µmol/l for women, b Hyperuricemia defined as UA ?458 µmol/l for men and ?393 µmol/l for women;
c Hyperuricemia defined as UA ?480 µmol/l; the rest using uric acid >420 µmol/l for men and >360 µmol/l for women.
2.1.2 Epidemiology of hyperuricemia
The prevalence of hyperuricemia varies markedly depending on the difference in
ethnic groups, geographic regions and survey years (Table 1). Among twenty three
studies (Al-Arfaj 2001; Brauer et al. 1978; Chang et al. 2001; Chen et al. 2007; Chen
et al. 1998; Chou et al. 1998; Conen et al. 2004; Darmawan et al. 1992; Fang et al.
1983; Fang et al. 2006; Jiang et al. 1999; Klemp et al. 1997; Ko et al. 2002; Lee et al.
2005; Li et al. 1997; Lin et al. 2000; Lohsoonthorn et al. 2006; Nagahama et al. 2004a;
Sturge et al. 1977; Tavares et al. 2003; Tuomilehto et al. 1988; Zimmet et al. 1978) that
used the hyperuricemia definition of > 420 ?mol/l  for  men  and  of  >  360 ?mol/l for
women, the prevalence of hyperuricemia ranged from 0.05% in Chinese women in
Shandong in 1995-1996 to 82.0% in male aborigines in Taiwan in 1993-1996. The
prevalence was lowest among Mainland Chinese and Indians in the Amazon region of
Brazil and highest among aborigines in Taiwan Mountainous area and Maori in New
Zealand in both men and women.
Trend studies in Caucasian (Gresser et al. 1990) and Han Chinese in Taiwan (Chang et
al. 2001; Lin et al. 2000) showed that the prevalence of hyperuricemia has increased
over past decades. A follow-up study of southern Germany (Gresser et al. 1990)
showed the UA levels have increased in both sexes over secular periods, since 1962,
1971, 1984, and 1989. The prevalence of hyperuricemia reached 2.6% for women and
28.6% for men in southern Germany in 1989. Early historical evidence suggests that
the Maori people of New Zealand were virtually untroubled by gout or obesity at the
time when these disorders were rife in the best fed and hardest drinking sections of the
northern European population (Rose 1975). During the past decades, with the
introduction of a western culture and diet, there has been a significant change. By the
mid 20th century, however, with an apparent decline of gout in Europe and North
America, hyperuricemia and gout appeared on a large scale in Maori and in other
indigenous inhabitants of the Pacific islands. Half the Polynesian population of New
Zealand, Rarotonga, Puka Puka, and the Tokelau Islands had hyperuricemia by
accepted European and North American standards. The associated gout rate reached
10.2% in Maori males aged 20 and over (Rose 1975). Studies of indigenous Pacific
populations  have  also  documented  that  the  serum  UA  is  higher  in  Maori  in  New
Zealand (Brauer et al. 1978; Klemp et al. 1997), Filipinos in Hawaii and Alaska
(Healey et al. 1966), and Chamorros and Carolinians in the Marianas Islands (Burch et
al. 1966).
The increase in serum UA levels, or the prevalence of hyperuricemia, appears to be
associated with the economic development (Wortmann 2002). For instance, the
Chinese emigrants in Malaya and western Canada have higher serum UA
concentrations than their relatives who live still in Taiwan (Ford et al. 1964), the urban
African black populations have higher serum UA levels than those with the same
ethnicities, but living in the rural community (Beighton et al. 1974).
It has also been noticed that serum UA levels tend to be higher in certain populations
(e.g., Pacific Islanders and Taiwan aborigines in high Mountainous area), with certain
phenotypes (obesity, metabolic syndrome), and with special diets (meat eaters) (Brauer
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et al. 1978; Chang et al. 1997; Klemp et al. 1997). Australian indigenous (Emmerson et
al. 1969) and Taiwanese aborigines have higher UA levels than Caucasian and Chinese
population in the same residential area, respectively (Chang et al. 2001). Taiwanese
aborigines are genetically related to the Malayo-Polynesians (Chang et al. 2001),
having a different genetic background compared to the Chinese population in Taiwan,
most of whom came from southern mainland China some 400 years ago and some of
whom arrived from the central and northern areas of mainland China 50 years ago
(Chou et al. 1998; Chungtei 2003). In addition, the higher prevalence of hypericemia
in Taiwanese aborigines, compared to other populations in Taiwan, is also associated
with a higher body mass index (BMI), and a higher consumption of alcohol and organ
meat, such as heart, kidney, and liver sweetbread (Chang et al. 2001; Chou et al. 1993).
2.2 Hyperuricemia associated with non-metabolic factors
2.2.1 Dietary factors
Dietary purine is an important exogenous source of UA. The transition of Western
lifestyle in developing counties or areas has been associated with increases in serum
UA levels and the prevalence of hyperuricemia (Kagan et al. 1974; Lennane et al.
1960). During the past couple centuries, large amounts of research demonstrated meat,
beef liver, seafood, haddock, and mushrooms as purine-rich food. An experimental
study (Brule et al. 1992) showed that a purine-rich diet increases serum UA 2-4 hours
post meals with a transient elevation with serum UA levels of 59-118 ?mol/l, whereas,
a purine-free diet, containing the same amount of calories, will take 7-10 days to
decrease serum UA levels by the same amount. The National Health and Nutrition
Examination Survey (NHANES) III (1988-1994) in the US, including 14 809
participants (6 932 men and 7 877 women) over 20, indicated that higher levels of
meat and seafood consumption are associated with higher serum UA levels, but that
total protein intake is not and dairy consumption is inversely associated (Choi et al.
2005). This was confirmed by a Dutch elder population study (Loenen et al. 1990).
Actually, a diet low in meat and high in dairy products had been considered protective
against gout since the 17th-19th centuries (Schlesinger 2005). Since dairy products are
low in purine content, dairy protein (casein and lactalbumin) may exert its uricosuric
effect without providing the concomitant purine load contained in other protein
sources, such as meat and seafood (Garrel et al. 1991).
Fructose is consumed in significant amounts in Western diet. An increase in fructose
consumption over the past 10-20 years has been linked with a rise in obesity and
metabolic disorders (Johnson et al. 2007; Le et al. 2006). Fructose intake may raise
serum UA levels by increasing adenosine triphosphate (ATP) degradation to adenosine
monophosphate (AMP), prompting activation of the pathway of purine degradation to
urate (Hallfrisch 1990; Mayes 1993). In contrast, glucose and other simple sugars do
not  have  this  effect  (Nakagawa  et  al.  2005).  It  is  also  suspected  that  the  cellular
mechanisms underlying the metabolic effects of fructose involve the production of
reactive oxygen species, activation of cellular stress pathways, and possibly an
increase in UA synthesis (Le et al. 2006). After studying recent research on association
of fructose, hyperuricemia, and cardiovascular diseases in humans, Johnson et al.
concluded that fructose and UA associated mechanisms are likely to be of more
importance in the initial development of the metabolic syndrome phenotype and may
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become less important once obesity, hypertension, and renal disease became
established (Johnson et al. 2007).
Tofu (soybean curd), a popular food among vegetarians in the Asian population, is rich
in protein, but most of the purines are lost during processing, and ingestion of tofu
produces only a small rise of serum UA in both healthy individuals and gout sufferers
(Yamakita et al. 1998). A study of Chinese vegetarians and omnivores found that the
omnivores had higher serum UA levels and lower insulin sensitivity than vegetarians,
and the degree of insulin sensitivity appeared to correlate with years on a vegetarian
diet (Kuo et al. 2004). A controlled randomized crossover designed trail evaluating the
metabolic effects of diets high in vegetable protein (specifically, wheat gluten) found
that high intakes of vegetable protein of gluten reduced oxidized low density
lipoproteins, triglycerides, and serum UA levels (Jenkins et al. 2001).
Alcohol consumption
Alcohol consumption is independently and significantly associated with hyperuricemia
and gout (Drum et al. 1981; Loenen et al. 1990; Lyu et al. 2003). In a 12-year cohort
study (Choi et al. 2004) using biannual questionnaires, Choi et al. found that moderate
regular consumption of beer was associated with gout incidence (the multivariate
adjusted relative risk of 1.49 per 12-oz beer serving per day). In contrast, moderate
wine consumption of 1-2 glasses per day did not increase the risk of development of
gout. Beer has a high purine content, predominantly as readily absorbable guanosine
and its intake enhances urate production, compounding the stimulatory effects of
alcohol metabolites on renal urate reabsorption (Yamamoto et al. 2002).
A number of mechanisms have been implicated in the pathogenesis of alcohol-induced
hyperuricemia. Ethanol increases urate synthesis by enhancing the turnover of adenine
nucleotides (Faller et al. 1982). Acute alcohol excess may cause temporary lactic
acidaemia, reduced renal urate excretion and induced hyperuricemia. Chronic alcohol
intake stimulates purine production by accelerating the degradation of ATP to AMP via
the conversion of acetate to acetyl-coA in the metabolism of alcohol (Sharpe 1984).
2.2.2 Other dietary and non-dietary factors
Cherries reportedly significantly reduce the plasma UA levels, irrespectively of
remaining time of consumption over hours or months (Jacob et al. 2003; Johnson et al.
2004), whereas, other fruits such as grapes, strawberries, and kiwifruit did not produce
the  same  effect.  Using  the  same  NHANES  III  data,  Choi  and  Curhan  (Choi  et  al.
2007a) examined the association of serum UA with coffee and tea intake. The results
showed that coffee consumption is associated with lower serum UA levels and
hyperuricemia frequency, but tea consumption is not. Serum UA levels associated with
the coffee intake of 4 to 5 and 6 cups or more daily was lower than that associated with
no intake by 15.5 ?mol/l (95% CI 6.5-24.4) and 25.6 mg/dl (95% CI 13.7-38.7), after
adjustments. Correspondingly, in the Health Professionals Follow-up Study (HPFS) of
47 150 males over a 12-year period follow-up, increasing coffee intake was inversely
associated  with  the  risk  of  gout  and  a  modest  inverse  association  was  also  found for
decaffeinated coffee, but not tea comsumption (Choi et al. 2007c). The absence of
association between serum urate levels and total caffeine and tea intake suggests that
components other than caffeine in the coffee have contributed to the inverse
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association. The mechanism behind this decreased risk of gout may be due to the effect
of  coffee  on  insulin  sensitivity  (Hak  et  al.  2008).  Higher  long-term  coffee  intake  is
associated with lower insulin levels (Wu et al. 2005) and improved insulin sensitivity
(Arnlov et al. 2004), whereas renal UA clearance is inversely related to the degree of
IR (Facchini et al. 1991; Muscelli et al. 1996; Ter Maaten et al. 1997). Thus increased
insulin sensitivity may lead to lower urate levels.
Diuretics are associated with hyperuricemia. Diuretics have an inhibitory effect on
renal excretions of UA. Some foods, including cranberry juice and asparagus, celery,
eggplant, lemon, garlic, cucumbers, and licorice, have a diuretic property that can
potentially increase serum UA levels (Schlesinger 2005). Fasting is also associated
with  a  rise  in  serum  UA  levels.  This  is  presumably  due  to  the  inhibitory  effect  of
ketones on UA excretion by the renal tubules for a short period (Maclachlan et al.
1967) and the dehydration for the month of Ramadan (Roky et al. 2004).
2.3 Hyperuricemia associated with metabolic risk factors
The main causes of high UA are shown in Table 2 (Becker et al. 2005).
Non-modifiable risk factors for hyperuricemia include genes, age, sex, and ethnic
group. Some studies of restricted populations (i.e., racially selected, geographically
isolated,  or  families  of  gouty  probands)  have  shown  a  bimodal  distribution  of  serum
urate values, supporting a single dominant gene hypothesis (Laskarzewski et al. 1983).
Nevertheless, abundant data indicate that serum UA concentration is continuously
distributed in both male and female general populations (Mikkelsen et al. 1965),
although skewed slightly toward higher values. Whether a single or multiple genes
determine the UA level in primary gout patients remains controversial (Becker 2002).
Table 2 Major causes of high uric acid concentration
Genetic causes
   Familial hyperuricemic nephropathy (mutation of uromodulin)
   Lesch-Nyan syndrome (HGPRT mutation)
   Phosphoribosyl pyrophosphate synthetase (PRPPS) mutation
Dietary causes
   Diet high in purines (organ meats, shellfish, fatty meats)
   Diet high in fructose (high fructose corn syrup, table sugar, honey)
   Ethanol
   Low sale diet
Drugs
   Thiazides
   Loop diuretics
   Calcineurin inhibitors (cyclosporine > tacrolimus)
   Pyrizinamide
   Low-dose aspirin
Volume depletion
Hypoxia (systemic or tissue)
Increased cell turnover (myeloproliferative disorders, polycythemia vera)
Conditions associated with higher uric acid levels
   Renal failure
   Obesity/metabolic syndrome
   Untreated hypertension
   African American race
   Preeclampsia
   Vigorous exercise
Reference:(Becker et al. 2005)
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2.3.1 Obesity
Obesity has reached epidemic proportions in the past decade and possibly represents
the most important component of the metabolic syndrome and an important risk factor
for type 2 diabetes. The association of hyperuricemia with obesity has been recognized
for hundreds of years (Wynagaarden et al. 1983). Hyperuricemia has been associated
with increasing BMI in early studies. A high correlation between serum UA and weight
and body surface area was found in American Indians in 1966 (O'Brien et al. 1966). In
the same year a similar association was discovered in European populations (Krizek
1966) and in a population of the Marian Island (Burch et al. 1966). The concept of
central obesity was first introduced by Vague in the 1940s (Vague 1947). Later on, in
1956, central obesity was indicated for the first time as being more important than
peripheral  obesity  in  relation  to  diabetes,  atherosclerosis,  gout,  and  urate  calculus
diseases. It has been shown in limited numbers of healthy and obese Japanese men (n =
50) that accumulation of visceral fat may have a greater adverse effect on the
metabolism of UA than BMI or accumulation of subcutaneous fat (Takahashi et al.
1997). Another study of obese Japanese men (n = 36) revealed that hyperuricemia in
those subjects with visceral fat obesity is related to UA overproduction, but not low
24-hour urinary urate excretion (Matsuura et al. 1998).
Recent follow-up studies further clarify the relationship between serum UA and
obesity.  The  Coronary  Artery  Risk  Development  In  young  Adults  (CARDIA)  cohort
study  (n  =  4  053)  has  shown  that  BMI  is  definitely  the  strongest  positive  factor
correlating with serum UA among components of the metabolic syndrome. The
significant associations of hyperuricemia with the metabolic risk factors appeared in
all sex-race groups. They persisted after controlling for possible confounders,
including age, education, physical activity, smoking, alcohol intake, oral contraceptive
use, and creatinine, but largely decreased further adjustment for BMI (Rathmann et al.
1998). In the NHANES I epidemiologic follow-up study (n = 5 926) (Fang et al. 2000),
serum UA values in the higher quartiles were associated with higher values of BMI in
both men and women. Another prospective study consisting of 433 young, non-obese,
normotensive  men  was  able  to  measure  BMI,  BP,  serum  UA,  and  other  items  every
year for 5 years and demonstrated that serum UA levels predict subsequent weight gain
and BP elevation (Masuo et al. 2003). In a 12-year follow-up study of 17 155 male
students at Okayama University in Japan (Ogura et al. 2004), the incidence of
hyperuricemia markedly increased in parallel with BMI and was also associated with
other metabolic risks, including hypercholesterolemia, fatty liver, and hypertension.
Obesity has several effects on UA metabolism, including increased UA production and
decreased renal UA clearance (Emmerson 1973). In obese subjects, hyperuricemia is
attributable to the overproduction of UA and impairment in the renal clearance of UA
owing to the influence of hyperinsulinemia secondary to IR (Matsuura et al. 1998;
Quinones  Galvan  et  al.  1995;  Yamashita  et  al.  1986).  Weight  reduction  is  associated
with a modest lowering of serum UA concentration and a decrease in the rate of de
novo purine synthesis (Emmerson 1973). In addition, the weight loss associated with
moderate calorie and carbohydrate restriction and increased proportional intake of
protein and unsaturated fat (as recommended for insulin-resistant states) is reported to
be accompanied by a decrease in serum UA levels and dyslipidemia in gout patients
(Dessein et al. 2000). Similarly, the amelioration of IR, by either a low-energy diet or
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troglitazone, decreased the serum UA levels in overweight hypertensive individuals
(Tsunoda et al. 2002).
A possible role of leptin in the relationship among hyperuricemia, obesity, and IR has
been addressed recently. Leptin, a hormone product of the OB (obese) gene, is
expressed in adipocytes and acts through the hypothalamus to regulate food intake and
energy expenditure. Most obese people show leptin resistance, and increased levels are
significantly associated with IR among nondiabetic individuals (Donahue et al. 1999).
Insulin responses, triglyceride levels, and BMI are independently and significantly
associated  with  leptin  concentrations  (Ruige  et  al.  1999).  Serum  UA  levels  correlate
positively with serum leptin in healthy male adolescents (Ogura et al. 2000) and in
moderately obese women (Garcia-Lorda et al. 2001). Matsubara et al. (Matsubara et al.
2002) found an independent relationship between serum leptin and UA among
Japanese women, even after adjusting for BMI and the percentage of body fat. Similar
findings  were  also  observed  among obese  children  (Moreno et  al.  2002).  Bedir  et  al.
have recently discussed the role of leptin as a possible regulator of UA concentrations
in humans and suspect that it might be a candidate for the missing link between obesity
and hyperuricemia (Bedir et al. 2003). These studies imply that the association of
serum UA, obesity, and IR may, at least in part, be mediated by leptin expression.
2.3.2 Dyslipidaemia
An association between hypertriglyceridemia and hyperuricemia is well established
(Barlow 1968). Up to 80% of individuals with hypertriglyceridemia have
hyperuricemia and 50% to 75% of gouty patients have hypertriglyceridemia. Obesity
and excessive alcohol intake may be confounders of the relations between
hypertriglyceridemia and hyperuricemia. In 108 gouty Japanese men,
hyperlipoproteinemia was seen in 56% and appeared to be independent of both alcohol
intake and obesity (Jiao et al. 1986).
Irrespective of central or peripheral type of obesity, however, it is not suspected that
dyslipidemia, especially hypertriglyceridemia to be involved and interacted in the
association  of  serum  UA.  More  recently,  free  fatty  acids  have  been  discovered  to  be
related to hyperuricemia independently of hypertriglyceridemia, obesity and central
body fat distribution (Bonora et al. 1996; Conen et al. 2004). Elevated serum total
cholesterol and triglycerides concentrations were observed among patients in the
highest tertile of serum UA levels compared to those in the lowest tertile, and an
inverse relationship was seen between HDL-C and serum UA levels (Matsubara et al.
2002). Concentrations of serum lipoprotein Lp(a) and apolipoproteins A-II, B, C-II, C-
III, and E were also reported as increased, while HDL–C decreased in patients with
gout (Takahashi et al. 1995). The prevalence of apolipoprotein E2 allele was greater in
gout patients, and its presence was associated with higher triglyceride levels in very
low-density lipoprotein and intermediate-density lipoproteins and with reduced renal
UA excretion (Cardona et al. 2003).
The potential mechanisms relating hyperuricemia to fasting hypertriglyceridemia are
unknown. It has been speculated that it may be due to an increase in nicotinamide
adenine dinucleotide phosphate oxidase (NADPH) requirement for de novo fatty acid
synthesis in obese subject (Vuorinen-Markkola et al. 1994). As noted elsewhere, UA is
produced by an enzyme, xanthine oxidoreductase, which catalyzes the reaction:
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Xanthine + NAD+ +  H2O = UA +NADH + H+. With increasing NADPH, UA
production is enhanced possibly increasing the serum UA level (Vuorinen-Markkola et
al. 1994). The current consensus is that the strongest association of UA is with fasting
triglyceride concentrations rather than with any direct measure of insulin sensitivity
(Schachter 2005). A corollary of these observations is that individuals with both
hyperuricemia and hyperlipidemia, particularly those with abdominal obesity, may be
at high-risk for type 2 diabetes and the cardiovascular diseases.
2.3.3 Hypertension
The relationship of UA to hypertension is independent of obesity, renal function, or
anti-hypertensive medications, especially thiazide diuretics (Heinig et al. 2006). This
association has been well demonstrated in many clinical and epidemiological studies
(Conen et al. 2004; Fang et al. 2000; Li et al. 1997). Hyperuricemia is common in
patients with essential hypertension. It appears that overall about 25% of hypertensive
individuals have hyperuricemia and this figure increases to 75% in those with
malignant hypertension (Cannon et al. 1966; Johnson et al. 2003). Studies suggest that
hyperuricemia in hypertensive subjects reflect early renal vascular involvement
associated with hypertension (Frohlich 1993; Messerli et al. 1980). Several studies,
however, found that elevated serum UA appeared in hypertension patients without
clinical renal dysfunction.
Univariate associations of hyperuricemia with both systolic and diastolic BP were
observed, but these relationships were attenuated after adjustment for BMI, suggesting
a major role of adiposity in this association (Wannamethee et al. 1997; Wannamethee
2005). Furthermore, results from most of population-based epidemiological studies
support hyperuricemia as a significant independent predictor for incident hypertension
by higher relative risk in Korean (Yoo et al. 2005), Italian (Jossa et al. 1994), Canadian
(Forman et al. 2007), black and white from US (Dyer et al. 1999; Mellen et al. 2006),
native Japanese (Nagahama et al. 2004a), and Japanese immigrants in US (Imazu et al.
2001).
On the other hand, new findings from a number of animal model experimental studies
shed light on a causal role for hyperuricemia in hypertension (Nakagawa et al. 2003;
Sanchez-Lozada et al. 2005; Sanchez-Lozada et al. 2006). For example, in Sprague-
Dawley rats (n = 69) (Mazzali et al. 2001), mild hyperuricemia was induced by
providing a uricase inhibitor (oxonic acid) in the diet. Experimentally induced
hyperuricemic rats developed elevated BP after 3 weeks, whereas control rats retained
normal BP. A dose-response relationship was observed between serum UA levels and
BP (r  =  0.75),  with  a  10  mm Hg BP increase  for  each  30  ?mol/l  increment  in  serum
UA levels. The induced elevation in BP in experimental rats was, however, partially
reversed by administration of enalapril, an angiotensin converting enzyme inhibitor, or
L-arginine, a substrate for nitric oxide production (Mazzali et al. 2001). This strongly
suggests that both angiotensin II and nitric oxide are involved in the pathogenesis of
the hypertension induced by UA.
The underlying mechanisms of increases in the UA level with essential hypertension
are still not well understood. Recent studies proposed the role of IR being the possible
pathophysiological link between an altered tubular sodium handling and UA
metabolism in humans (Cappuccio et al. 1993; Facchini et al. 1991; Frohlich 1993;
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Lee et al. 1995; Rathmann et al. 1998). The epidemiologic support for such a role in
humans has also been reviewed by Johnson et al. (Johnson et al. 2005b). The
relationship between serum UA and BP was hypothesized as resulting from a uricase
mutation that occurred during early hominoid evolution, which was originally
advantageous because it helped to maintain BP both acutely (via stimulation of the
renin angiotensin system) and chronically (by inducing salt-sensitivity via the
development of renal microvascular and interstitial disease) (Watanabe et al. 2002). In
modern  society,  the  switch  to  a  westernized  diet  rich  in  high  salt  and  fatty  meat,
coupled with this mutation, may have played an important role in the current epidemic
of hypertension and cardiovascular diseases (Johnson et al. 2005b). Acute
hyperinsulinemia does not affect serum UA levels, but it does cause a marked decrease
in the urinary excretion of UA accompanied by decreased sodium and potassium
excretion (Muscelli et al. 1996). Furthermore, it has been demonstrated that high UA
levels are independently associated with increased tubular sodium resorption in men
(Cappuccio et al. 1993). The predictive value of hyperuricemia in respect to
cardiovascular outcome does not weaken by adjustment for the components of
metabolic syndrome, including fasting insulin levels (Niskanen et al. 2004).
2.3.4 Insulin resistance
The Bruneck Study, based on a random sample of the general population (n = 888,
aged 40-79), reported that the prevalence of IR is 62.8% in subjects with
hyperuricemia (Bonora et al. 1998). IR is probably one of the underlying conditions
triggering the development of the above metabolic disorders. It has been reported that
the degree of IR (measured in everyday practice by the homeostasis model assessment
index and the quantitative insulin sensitivity check index) (Pacini et al. 2003) may be
directly related to serum UA levels (Modan et al. 1987; Vuorinen-Markkola et al.
1994).
The increased purine biosynthesis and turnover, with consequent increases in serum
UA concentrations caused by the increased activity of the hexose monophosphate
shunt, may be linked to IR and/or hyperinsulinemia (Modan et al. 1987). Especially,
the impairment of the glycolytic pathway can increase the flux of glucose-6-phosphate
through the hexose monophosphate shunt, resulting in the accumulation of
ribose-5-phosphate and other intermediates, which are major substrates for UA
production (Fox 1981; Fox et al. 1985). On the other hand, there is evidence that UA
may not only be a consequence of IR, but it may actually promote or worsen IR.
Moreover, a recent study (Nakagawa et al. 2006) showed that UA plays an important
role in the pathogenesis of metabolic syndrome, probably due to its ability to inhibit
endothelial function through inhibiting nitric oxide bioavailability (Baldus et al. 2005).
Since insulin needs nitric oxide to stimulate glucose uptake, the investigators
hypothesized that hyperuricemia may have a key role in the pathogenesis of IR
(Nakagawa et al. 2006).
In addition, drugs that improve insulin sensitivity, such as metformin (Gokcel et al.
2002), troglitazone (Tsunoda et al. 2002), sibutramine (Filippatos et al. 2005;
Tambascia et al. 2003), and orlistat (Gokcel et al. 2002; Kiortsis et al. 2005) can also
lower UA levels. Furthermore, insulin receptors were found in different tubular
segments of human kidney (Nakamura et al. 1983). Insulin can enhance renal proximal
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tubular  UA  reabsorption  in  humans  due  to  an  active  transport  mechanism  closely
linked to the tubular reabsorption of sodium (Cappuccio et al. 1993; Muscelli et al.
1996; Quinones Galvan et al. 1995). Whatever the site of the tubular effects of insulin,
the possible mechanisms linking hyperinsulinemia (a consequence of IR) with
hyperuricemia include the direct stimulations of tubular ion (UA-Na) exchange or the
acceleration of cellular metabolism (Mandel 1986).
2.3.5 Hyperglycemia and diabetes
Diabetes mellitus is a metabolic disorder of multiple etiologies characterized by
chronic hyperglycemia with disturbances of carbohydrate, fat, and protein metabolism
resulting from defects in insulin secretion, insulin action, or both (World Health
Organisation 1999). Diabetes is defined according to elevated glucose levels,
FPG ? 7.0 mmol/l and/or 2-hour plasma glucose (2-hPG) ? 11.1 mmol/l by the latest
WHO criteria (World Health Organisation/International Diabetes Federation 2006).
Type 2 diabetes is characterized by IR and relative insulin deficiency, either of which
may be present at the time that diabetes becomes clinically manifested (Reaven et al.
1976; Tuomilehto et al. 2001). The specific reasons for the development of these
abnormalities are not yet known, but the general reasons are population aging,
unhealthy diet, overweight and obesity, and a sedentary lifestyle.
In 2007, it was estimated that 7.3% of adults aged 20-79 in all International Diabetes
Federation (IDF) member countries had diabetes. In 1985, an estimated 30 million
people worldwide had diabetes. In 2000, a little over a decade later, the figure had
risen to over 150 million. By 2025, the figure is expected to rise to 380 million
(International Diabetes Federation 2008). Approximately 85% to 95% of all diabetes
cases are estimated to be type 2 diabetes in developed countries, and account for an
even higher percentage in developing countries.
The long-term effects of diabetes are largely due to the fact that virtually all tissues of
the  body  are  exposed  to  high  glucose,  and  include  a  progressive  development  of  the
specific microvascular complications such as retinopathy with potential blindness,
nephropathy that may lead to renal failure, and neuropathy with risk of foot ulcers,
amputation, and features of autonomic nervous dysfunction. In addition, people with
diabetes are at an increased risk of macrovascular complications including coronary
heart disease, peripheral vascular and cerebrovascular disease, and most diabetic
patients die from cardiovascular disease. Therefore, huge premature morbidity and
mortality are associated with the disease (Boyko et al. 2000).
Since World War II, the southern Indian Ocean island of Mauritius has experienced a
rising standard of living associated with industrialization, and there has been a marked
secular increase in prevalence of diabetes. The prevalence of type 2 diabetes increased
significantly from 12.8% in 1987 to 15.2% in 1992 and 17.9% in 1998 (Soderberg et
al. 2005). China, which is the largest developing country and has the largest population
in the world, has also experienced high-speed socio-economic development during
past two decades, accompanied by a rapid increase in the prevalence of obesity and
diabetes. National population based studies made in mainland China, indicate sharply
rising prevalence rates of diabetes in Chinese adults, three-fold from approximately
1% in 1980 to 3.2% in 1996 (National Diabetes Co-operative Study Group 1981;
Xiang et al. 1998). In Qingdao city a diabetes survey in 2001-2002 showed that the
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age-standardized prevalence of diabetes was 6.1% (4.1% for undiagnosed and 2.1% for
previous diagnosed diabetes) in adults aged 20-74 (Dong et al. 2005).
2.3.5.1 UA and its changes with pre-diabetes and type 2 diabetes
Previous cross-sectional studies have shown that diabetic patients have low UA levels.
In the Japanese-American population in Hawaii (n = 8 000, men), subjects with a prior
history of diabetes have lower serum UA levels than those without (Yano et al. 1977).
UA was significantly elevated in people with IGT and significantly lower in those with
diabetes in Melanesians and Asian Indians (Tuomilehto et al. 1988), increased with
FPG up to 7.0 mmol/l in men and to 9.0 mmol/l in women but significantly decreased
thereafter  in  Caucasians  (Whitehead  et  al.  1992),  and  increased  with  increasing  FPG
levels up to 8.0 mmol/l in middle-aged British men (Cook et al. 1986). Cook et al.
concluded that the positive relationship between serum UA and plasma glucose could
not  be  explained  by  associations  with  BMI,  alcohol  intake,  age,  social  class,  gout,  or
treatment for hypertension. It probably reflected the biochemical interaction between
plasma glucose and purine metabolism, with increased excretions of UA during
hyperglycemia and glycosuria (Cook et al. 1986). Another population-based
cross-sectional study indicated serum UA strongly correlated with 2-hPG (p < 0.001)
in nondiabetic Mauritian men (r = 0.15) and women (r = 0.22) (Hodge et al. 2001).
In  the  Israeli  Heart  Disease  Study,  10  000  men,  age  40,  from  a  random  selection  of
government and municipal workers were examined at the baseline in 1963 and
re-examined in 1965 and 1968 by using a same glucose tolerance test. This study
showed that baseline serum UA levels were higher in individuals who were pre-
diabetes at baseline, but developed diabetes at the end of follow-up, as compared to
individuals who were free of diabetes at the end of follow-up. In those who developed
diabetes during the follow-up, the UA levels were lower at the diagnosis of diabetes
than at baseline and the UA levels continued to decrease with the duration of diabetes
(Herman et al. 1976).
2.3.5.2 UA and incident type 2 diabetes
A few studies have investigated the association of serum UA with incident type 2
diabetes (Table 3), but most of these studies were conducted only on the male
population. In those early prospective studies, for example, it was reported that for a
1 mg/dl increase in baseline UA levels a 1.14-fold increase in risk of incident diabetes
was observed during a 5-year follow-up period in middle-aged Israeli men (Medalie et
al. 1975). Among a randomized sample (n = 766) of men, age 54, from an urban area
in Sweden, the multivariate adjusted risk for the development of diabetes during a
13.5-year follow-up was 5.8-fold for those in the top quintile of serum UA values
compared to those in the lowest quintile (Ohlson et al. 1988).
The British Regional Heart Study (BRHPS) was designed to determine the risk factors
for type 2 diabetes during a 12.8-year follow-up period in a cohort of 7 735 men, age
40-59, drawn from the age-sex register of one general practice in each of 24 towns in
England, Wales, and Scotland between January 1978 and June 1980 (Perry et al. 1995).
The BRHPS found that subjects whose baseline serum UA values were in top quintile
of the distribution had 1.5-fold higher risk for diabetes than those in the lowest
quintile. Similar to BRHPS, a Japanese study has shown that a high baseline UA level
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was associated with an increased risk of diabetes over a 6-year follow-up in male
office workers, age 35-39, who did not have hypertension, impaired fasting glycemia
(IFG), type 2 diabetes, or past history of cardiovascular disease (Nakanishi et al.
2003).
A few population-based prospective studies have assessed the relationship between UA
and diabetes in women (Table 3). Monica Augsburg Cohort Study is the first
population-based prospective study that explored the prediction of serum UA for
development of diabetes in Germany (Meisinger et al. 2002). This study reported that
baseline serum UA was a strong independent risk factor for diabetes in women, with a
multivariable adjusted hazard ratio (95% CI) of 2.1 (1.5-2.8). Another study in the
Chinese population of Taiwan (Lin et al. 2004) indicated that high UA levels at
baseline examination independently predicted the development of diabetes in women
with  an  odds  ratio  of  1.44,  but  not  in  men.  More  recently,  it  has  been  shown  that
baseline plasma UA is an independent predictor of future type 2 diabetes incidence in a
community-based prospective cohort study of 2 690 Chinese participants (age 35-97)
in Chin-Shan town, Taiwan (Chien et al. 2008). The relationship between FPG and
2-hPG concentration and serum UA level in nondiabetic population, however, is still
unknown. The baseline serum UA levels have been found to independently predict the
2-hPG level 13.5 years later in Swedish male population, with a low regression
coefficient of 0.01 (p = 0.026) (Ohlson et al. 1988). In the Finnish Diabetes Prevention
Study (Niskanen et al. 2006) in high-risk middle-aged subjects with IGT, baseline UA
and its changes predicted a 2-fold increase in the likelihood of developing type 2
diabetes. Furthermore, UA and its changes during follow-up were related to
corresponding changes in FPG and 2-hPG (Niskanen et al. 2006).
Table 3 Prospective studies on the relationship between serum uric acid and incident diabetes
Study Study region Baseline
study year
Population,
Age (y)
Follow-
up years
Hazard ratio
(95% CI)
Adjustment variables Reference
Israeli Heart Disease
Study
Israel 1963 10 000 Men,
age ?40
5 1.14 per 1 mg/dl Age, BMI, SBP, total cholesterol, hemoglobin,
education, and birthplace
(Medalie et al.
1975)
Swedish Study Gothenburg,
Sweden
1967 766 Men,
mean age 54
13.5 Q5 vs. Q1
5.8(2.2-16.0)
Age, BMI (WHR), SBP (DBP), FPG,
triglycerides, GOT(GPT), and Bilirubin
(Ohlson et al.
1988)
British Regional Heart
Study
Great Britain 1977-
1980
7 735 Men,
age 40-59
12.8 Q5 vs. Q1
1.5 (0.9-2.5)
Age, BMI, SBP, HDL-C, smoking and alcohol
drinking status, prevalent CHD, heart rate, and
physical activity
(Perry et al.
1995)
Monica Augsburg
Cohort Study
Augsburg,
Germany
1984-
1995
3 052 Men and
3 114 Women,
age 35-74
3-15 Men 1.1 (0.9-1.4),
women 2.2 (1.6-3.0)
per 1mmol/l
Age, BMI, SBP, HDL-C, smoking and alcohol
drinking status, family history of DM, physical
activity, and cohort
(Meisinger et
al. 2002)
Japanese office worker
Study
Japan 1994 2 310 Men,
age 39-59
6 Q5 vs. Q1
1.78 (1.11-2.85)
Age, BMI, family history of diabetes, cigarette
smoking, alcohol intake, regular physical
exercise, mean BP, FPG, triglycerides, total
cholesterol, and HDL-C
(Nakanishi et
al. 2003)
Hyperuricemic
Chinese Study
Taiwan 1991-
1992
391 Men and
250 Women,
age ?30
7 Men 0.76 (0.51-
1.22), Women 1.44
(1.13-2.25) per 1
mg/dl
Age, FPG, BMI, SBP (DBP), menopause status
(women), HDL-C, serum creatinine,
triglyceride, total cholesterol, and fasting serum
insulin
(Lin et al.
2004)
Community
Cardiovascular Cohort
Study
Taiwan 1990 1 392 Men and
1 566 Women,
age ?35
9 Q5 vs. Q1 1.40
(1.02-1.92) for total
population
Age, sex, BMI, SBP (DBP), FPG, triglycerides,
HDL-C, alcohol intake, marital status, education
level, occupation, and family history of diabetes.
(Chien et al.
2008)
Rotterdam Study Netherlands 1990-
1993
4 536 Men and
women,
age ?55
10.1 Quartile 4 vs.
Quartile 1 1.68
(1.22-2.30)
Age, sex, BMI, waist circumference, SBP. DBP,
and HDL-C
(Dehghan et
al. 2008)
Q5, quintile 5 or top quintile; Q1, quintile 1 or the lowest quintile. BMI, body mass index; SBP,  systolic blood pressure; DBP, diastolic  blood pressure; WHR, waist to hip ratio;
HDL-C, high density lipoprotein -cholesterol; FPG, fasting plasma glucose; GOT/GPT, human aspartate aminotransferase.
2.3.6 Metabolic syndrome
The clustering of resistance to insulin-stimulated glucose uptake, hyperinsulinemia,
hyperglycemia, hyperuricemia, increased very low-density lipoprotein, triglycerides,
decreased high-density lipoprotein cholesterol (HDL-C), and hypertension has been
noticed and described since 1923 (Kylin 1923) named later as "syndrome X" (Reaven
1988) or “IR syndrome” (Haffner et al. 1992) or more recently the “metabolic
syndrome” (Grundy 1999). The co-morbidities associated with hyperuricemia include
obesity, hyperlipidemia, hypertension, IR, hyperglycemia, cardiovascular diseases
(coronary artery disease and stroke), and chronic renal disease (Johnson et al. 2003).
Although hyperuricimia was not included in the recent major definitions for the
metabolic syndrome by the WHO, the National Cholesterol Education Program Adult
Treatment Expert Panel III (NCEP), and the IDF (Adult Treatment Panel III 2002;
Alberti et al. 2005, 2006; Expert panel on detection, evaluation, and treatment of high
blood cholesterol in adults 2001; World Health Orgnisation 1999), continuing debating
ensues on whether hyperuricemia is an additional component of the metabolic
syndrome  (Liou  et  al.  2006;  Zavaroni  et  al.  1993).  This  indicates  the  role  of  the
hyperuricemia is still less known.
The prevalence of the metabolic syndrome varies markedly depending on the
definitions used and populations studied (Qiao et al. 2007). Among 22 studies that
used the original full definition of the NCEP, the prevalence of the metabolic syndrome
ranged from 5.6% in Chinese women in Hong Kong to 52.8% in Polynesian men in
New Zealand. A more recent study (Lee et al. 2008) aiming to compare the age-
adjusted prevalence of metabolic syndrome by different definitions in Asia-Pacific
populations from Australia, Japan, Korea, and Samoa, indicated that Japanese people
had the lowest prevalence of metabolic syndrome regardless of the definition and
Samoans generally had the highest prevalence. Regarding the differences in the
prevalence of metabolic syndrome and its components by using the various definitions,
both within and between populations, researchers concluded that standardization of the
methodology is gravely required when comparing studies from different countries.
The metabolic syndrome increased the risk of the development of type 2 diabetes and
cardiovascular disease (DECODE Study Group 2006; Ford 2004), and the prediction is
stronger for type 2 diabetes than for cardiovascular disease (Stern et al. 2004). Studies
have also shown, however, that individual metabolic components predicted the
cardiovascular diseases risk by a similar magnitude to that of the actual syndrome
(DECODE Study Group 2006; Ford 2004; Hunt et al. 2004; Lawlor et al. 2006).
Research addressing the issue regarding the cardiovascular disease risk prediction of
an actual syndrome and its single individual component are required. In addition, to
what extent the other factors that are not included in the current definition of the
metabolic syndrome, including hyperuricemia, have contributed to the cluster and the
increased risk of diabetes and cardiovascular disease is much less known.
Prevalence of metabolic syndrome in Mauritius and China
According to the non-communicable diseases surveys in 1987 in Mauritius, including
known or newly diagnosed diabetes, the metabolic syndrome prevalence varied
between 14.1% (95% CI 13.0–15.3) for the IDF, 19.6% (95% CI 18.3–20.9) for the
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NCEP and 20.4% (95% CI 19.1–21.7) for the WHO definition (Cameron et al. 2007).
The corresponding figures, after exclusion of those with diabetes, were 10.7%
(9.6-11.7), 14.2% (13.0–15.4) and 14.6% (13.4–15.8) in the same study. The
prevalence of the NCEP and IDF metabolic syndrome definitions were significantly
higher among Creoles [19.2% (16.4–21.9) and 14.2% (11.8–16.6)] than Indians
[12.2% (10.8–13.6) and 9.5% (8.2–10.7); both p < 0. 05], however, no significant
difference in the prevalence of the WHO definition of the metabolic syndrome was
observed among the three ethnic groups of Indian, Creole and Chinese (Cameron et al.
2007).
The International Collaborative Study of Cardiovascular Disease in Asia was
conducted in China and Thailand between 2000 and 2001, including a nationally
representative sample of 15 540 individuals from ten provinces of China. The study
revealed that 19.4% of Chinese adults, age 35-74, have hypertension, 24.8% have
raised triglycerides levels, and 33.9% have low HDL cholesterol (Gu et al. 2005; He et
al. 2004; Huang et al. 2004). A recent study (He et al. 2007) reported that according to
the WHO definition for overweight (BMI ? 25.0 kg/m2)  and  the  IDF  criteria  for
metabolic syndrome, prevalence rates for overweight and metabolic syndrome were
56.3% (53.9% in men and 57.9% in women) and 46.3% (34.8% in men and 54.1% in
women), in individuals 60-year old or younger living in a community in Haidian
District, a metropolitan area representative of the geographic and economic
characteristics in Beijing, China. In mainland China, in 2000-2001 (Yang et al. 2007),
the overall age-standardized prevalence of the metabolic syndrome among a nationally
representative sample of 15 838 Chinese adults, age 35-74, was 16.5% and 23.3%,
according to the IDF and revised NCEP definitions. The prevalence significantly
increased with age and was higher in women than in men by both definitions (23.3%
vs. 10.0% for IDF and 29.1% vs. 17.7% for revised NCEP, p < 0.001). Compared to
men, women had a significantly higher prevalence of central obesity (37.6% vs.
16.0%) and reduced HDL-C (46.5% vs. 21.9%), whereas men had a significantly
higher  prevalence  of  raised  BP  (44.2%  vs.  38.0%)  compared  to  women  (Yang  et  al.
2007).
UA associated with metabolic syndrome
The association between serum UA and the metabolic syndrome is also illustrated by
the fact that the prevalence of metabolic syndrome shows a graded increase with
increased serum UA levels from large population based epidemiologic studies in
different ethnic groups (Boyko et al. 2000; Ishizaka et al. 2005; Klein et al. 2002; Yoo
et al. 2005). A recent analysis of the NHANES III (Choi et al. 2007b) showed that the
prevalence of the metabolic syndrome increases substantially with increasing levels of
serum UA. The prevalence of the metabolic syndrome (NCEP criteria) ranged from
18.9% (95% CI 16.8–21.0) for UA levels less than 6.0 mg/dl, to 70.7% (95% CI 51.4–
89.9) for UA levels equal to or above 10.0 mg/dl, and the increasing trends persisted in
subgroups stratified by sex, age, alcohol intake, BMI, hypertension, and diabetes.
Recently, a cross-sectional study in the healthy Thai population (inclusion criteria: no
previously diagnosed diabetes, hypertension, gout, and not taking UA- lipid- or BP-
lowering medication) addressed that elevated serum UA (top quartile) conveyed a
3.9-fold high risk of the metabolic syndrome (defined by the modified NCEP criteria)
in men and 2-fold in women (Lohsoonthorn et  al.  2006).  The association of UA with
metabolic syndrome, however, still needs to be delineated in other population samples.
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2.4 Hyperuricemia and cardiovascular diseases
2.4.1 Associations of hyperuricemia with cardiovascular diseases
The positive association between serum UA and coronary heart disease and
cardiovascular disease has been recognized for 50 years (Gertler et al. 1951; Klein et
al. 1973). The issue of hyperuricemia as an independent risk factor for atherosclerotic
cardiovascular disease has received much renewed interest in recent years with many
reviews and editorials providing different views (Alderman et al. 2004; Dobson 1999;
Johnson et al. 1999; Yusuf et al. 2002), and some studies providing conflicting results
(Culleton et al. 1999; Fang et al. 2000; Liese et al. 1999; Wannamethee et al. 1997).
The Framingham study (Culleton et al. 1999), including 6 763 subjects whose baseline
serum UA levels were tested from 1971 to 1976, supported the contention that
traditional risk factors, rather than hyperuricemia, are the primary casual factors in
development of atherosclerotic heart disease during follow-up. In this study,
hyperuricemia was not associated with an increased risk for adverse outcomes
(coronary heart disease, death from cardiovascular disease, or death from all causes)
after adjustment for other cardiovascular risk factors in men and women.
Nevertheless in another nationwide survey, the NHANES I study of 5 926 subjects
followed-up for an average of 16.4 years found that the increasing serum UA
concentration was related to increased cardiovascular mortality in both sexes and
ethnic groups (Fang et al. 2000). Death due to ischemic heart disease and overall
cardiovascular mortality rates increased in relation to UA quartiles (relative risk, 1.77
in  men  and  3.00  in  women),  even  after  adjustment  for  age,  race,  BMI,  smoking,
alcohol intake, cholesterol, hypertension, and diabetes. Recently, a study of
1 017 patients with angiographically proven coronary artery disease has shown a
5-fold increase in overall mortality rates among patients with serum UA levels in the
top  quartile,  compared  to  those  in  the  lowest  quartile.  In  addition,  serum UA was  an
independent predictor of mortality in patients with coronary artery disease after
adjustment for 12 variables (including diuretic use) that influence overall
cardiovascular mortality (Bickel et al. 2002). In patients with well-controlled
hypertension, cardiovascular mortality was significantly greater among hyperuricemic
individuals than among their normouricemic counterparts (Alderman et al. 1999).
More recently, elevated serum UA has been shown as being an independent predictor
of mortality in high-risk groups including subjects with hypertension, coronary heart
disease (Hoieggen et al. 2004), stroke (Weir et al. 2003), diabetes, and heart failure
(Gerber et al. 2006). The similar result has been further confirmed in a population-
based cohort study of a 12-year follow-up in middle-aged healthy Finnish men
(Niskanen et al. 2004).
Johnson et al. (Johnson et al. 2003) summarized that hyperuricemia predicted the
development of cardiovascular disease, not only in individuals with hypertension or
pre-existing cardiovascular disease but also in the general population. Whereas,
Wheeler et al. (Wheeler et al. 2005) considered that measurement of serum UA levels
is unlikely to usefully enhance the prediction of coronary heart disease nor to be a
major determinant of the disease in general populations based on the results of a meta-
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analysis of data from 15 prospective studies. Although some studies suggested that
serum UA is an independent risk factor for coronary heart disease (Fang et al. 2000;
Freedman et al. 1995; Gertler et al. 1951; Liese et al. 1999), there is still more
evidence that the association of hyperuricemia with coronary heart disease events is
dependent on the association between serum UA and other risk factors, such as
hypertension, obesity, and elevated levels of triglycerides (Culleton et al. 1999;
Freedman et al. 1995; Jee et al. 2004; Wannamethee et al. 1997; Yano et al. 1984). This
evidence suggests that the influence of UA on coronary heart disease is explained by
the secondary association of UA with other established etiological risk factors
(hypertension, dyslipidemia, hyperinsulinemia, obesity, and pre-existing disease)
(Wannamethee 2005).
A causal role for hyperuricemia in cardiovascular disease events and mortality has not
been unequivocally established (Johnson et al. 2003). Serum UA may, however,
provide useful prognostic information in subjects with hypertension and vascular
disease (Wannamethee 2005).
2.4.2 Underlying mechanisms
2.4.2.1   Antioxidant – prooxidant UA redox shuttle
The term “Oxidative Stress” generally was denoted “the disturbance in
prooxidant-antioxidant balance in favor of the former” in 1985 by Helmut Sies (Sies
et al. 1985). The interest for elucidating the molecular mechanisms underlying the
effects of oxidative stress on cells has been greatly increased during the past few years,
mainly due to proposals indicating its involvement in many physiological and
pathological conditions, including aging, cancer, and atheriosclerosis (Glantzounis et
al. 2005). It should be noted that low levels of reactive oxygen species are
continuously present in cells under physiological conditions and the cellular redox
state is tightly regulated. The toxic effects of reactive oxygen species become apparent
only when the rate of their generation increases and the defence capacity of cells are
overwhelmed. Oxidative stress has been regarded broadly as a mediator in the process
of development of cardiovascular disease (Berges et al. 2003; Linke et al. 2003).
Oxidative  stress  may  also  play  a  role  in  the  pathogenesis  of  diabetes,  associated
cardiac dysfunction, general vascular dysfunction, and the metabolic syndrome
(Channon et al. 2002; Deedwania 2003).
Serum  UA  in  the  early  stages  of  the  atherosclerotic  process  is  known  to  act  as  an
antioxidant and may be one of the strongest contents of plasma antioxidative capacity
(Glantzounis et al. 2005; Nyyssonen et al. 1997). Intriguingly, the simple concept is
that serum UA in patients with cardiovascular disease, the metabolic syndrome, type 2
diabetes, hypertension, and renal disease may reflect a compensatory mechanism to
counter  oxidative  stress.  This  is  not,  however,  able  to  explain  why higher  serum UA
levels in patients with these diseases are generally associated with worse outcomes
(Johnson et al. 2003).
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Figure 1. (Hayden et al. 2004) Antioxidant – prooxidant urate redox shuttle. This shuttle is important in
understanding the role of how the antioxidant uric aicd (UA) becomes prooxidant in this environmental
milieu, which results in its damaging role to the endothelium and arterial vessel wall remodeling with an
elevated tension of oxidative – redox stress (ROS), accelerated atherosclerosis and arterial vessel wall
remodeling.
Unfortunately, later in the atherosclerotic process when serum UA levels reach above
the normal range 357 ?mol/l in females and 387–416 ?mol/l in males, the previously
antioxidant (UA) paradoxically becomes prooxidant (Fang et al. 2000; Niskanen et al.
2004). This antioxidant – prooxidant UA redox shuttle (Figure 1) seems dependent on
its surrounding environment such as timing (early or late in the disease process),
location of the tissue and substrate, acidity (acidic–, basic– or neutral PH value), the
surrounding oxidant milieu, the depletion of other local antioxidants, and the supply
and duration of oxidant substrate and its oxidant enzyme. Depletion of local
antioxidants with an underlying increase in oxidantive-redox stress is associated with
the uncoupling of the endothelial nitric oxide synthase enzyme, then a decrease in the
locally produced naturally occurring antioxidants, endothelial nitric oxide and
endothelial dysfunction (Hayden et al. 2004). This process is also occurs within the
microvascular bed at the level of the capillaries within various affected hypertensive
and diabetic end organs (Bagnati et al. 1999; Hayden et al. 2004; Patterson et al. 2003).
Recent experimental studies (Bagnati et al. 1999; Nyyssonen et al. 1997; Patterson et
al. 2003; Sanguinetti et al. 2004) have explored the formation of UA being connected
with the conversion of xanthine dehydrogenase to xanthine oxidase leading to
concomitant production of free radicals. Glantzounis et al. (Glantzounis et al. 2005)
showed that besides well-known reasons for an increase in the serum UA level stands
another poorly recognized factor, i.e. local ischemia, from the metabolism of
hypoxanthine-xanthine by the enzyme xanthine oxidoreductase. In this respect, it is
worth noting that xanthine oxidoreductase occurs in two different forms. Xanthine
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dehydrogenase is the prevalent operative form under physiological conditions and has
greater affinity for oxidized nicotinamide adenine dinucleotide compared with oxygen,
as the electron acceptor. Under ischemic conditions, in parallel to the degradation of
ATP into adenine, an interconversion of xanthine dehydrogenase to xanthine oxidase
takes place. The latter utilizes molecular oxygen in place of oxidized nicotinamide
adenine dinucleotide as an electron acceptor, leading to the formation of superoxide
anion and hydrogen peroxide in parallel with UA production (Glantzounis et al. 2005).
2.4.2.2   Serum UA and inflammation
Increased serum UA was closely associated with systemic inflammation, such as
elevated C-reactive protein (Anker et al. 2003), stimulation of release of chemokine
monocyte chemoattractant protein-1(Kanellis et al. 2003), interleukin-6, and tumor
necrosis factor-? synthesis (Johnson et al. 2005a). Serum UA has been shown to have a
significant positive correlation with C-reactive protein in Japanese men (n = 3 692,
aged 34–69) (Tamakoshi et al. 2003), in a German population-based study (n = 1 703,
aged 18-89) (Frohlich et al. 2000), and in a representative random sample
of  957 individuals, age 65-95, of the Italian general population (Ruggiero et al. 2006).
In the Italian study (Ruggiero et al. 2006), the association between UA and C-reactive
protein was independent of multiple confounders of white blood cells, neutrophil
count, interleukin-6, interleukin-1 receptor antagonist, interleukin-18, and tumor
necrosis factor-?. The relationship of UA with inflammatory markers is linear across
the entire range of UA level.
Moreover, a follow-up study (Ruggiero et al. 2007) in the same Italian cohort found
that: (1) baseline UA and changes in UA from baseline to follow-up were significant
predictors of C-reactive protein changes during a 3-year follow-up, independently of
baseline inflammatory markers and relevant confounders; (2) subjects in the fourth and
fifth UA quintiles had a higher probability of developing clinically relevant increased
interleukin-6 (> 2.5 pg/ml) and C-reactive protein (> 3 mg/l) during the 3-year follow-
up  period,  compared  to  those  in  the  second  quintile.  A  clinical  study  of  a  sample  of
30  patients  concluded  that  serum UA may reflect  the  severity  of  systolic  dysfunction
and the activation of inflammation in patients with congestive heart failure (Olexa
et al. 2002).
Serum UA elevation may indeed be a sensitive marker for underlying vascular
inflammation and remodeling within the arterial vessel wall and capillary interstitium.
Some evidence suggests that UA may exert a negative effect on cardiovascular disease
by stimulating inflammation, which is clearly involved in the pathogenesis of
cardiovascular disease (Festa et al. 2005; Hansson 2005). Is it possible that serum UA
levels could be as similarly predictive as C-reactive protein since it is a sensitive
marker for underlying inflammation and remodeling within the arterial vessel wall and
the myocardium? It is not surprising that these two markers of risk track together
within the metabolic syndrome and cardiovascular disease (Hayden et al. 2004). In
spite of the evidence that UA might contribute to the development of human vascular
disease and atherosclerosis, through a pro-inflammatory pathway, the relationship
between UA and inflammation has been less investigated and needs further
exploration.
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2.4.2.3   Endothelial dysfunction
The endothelium represents a single layer of cells that line all vessels in the body,
including the conduit vessels, the resistance vessels, precapillary arterioles, and
capillaries (Vane et al. 1990). By virtue of its direct contact with the circulating blood,
the endothelial layer provides a critical interface between the elements of blood and the
tissues. The function of each vessel and the role of its respective endothelium vary
according to its location in the body. Vascular endothelial dysfunction may occur at
any level in the arterial system and contributes to the development and progression of
atherosclerosis by favoring coagulation, cell adhesion and inflammation, through
promoting inappropriate vasoconstriction and/or vasodilation, and by enhancing
transendothelial transport of atherogenice lipoproteins.
Furthermore, endothelial dysfunction involves a very early stage of vascular disease
(Aengevaeren 1999). Since one of the major sites of the production of UA in the
cardiovascular  system  is  the  vessel  wall  and  particularly  the  endothelium  (Becker
1993) and UA’s ability to inhibit endothelial function through inhibiting nitric oxide
bioavailability (Baldus et al. 2005), elevated serum UA may be a marker of endothelial
dysfunction. It has been shown that UA concentrations correlated inversely with
flow-mediated brachial artery vasodilation in vivo (Maxwell et al. 2001). Moreover, in
a controlled setting of dietary treatment with an arginine-enriched nutrient bar, which
enhances nitric oxide activity, the increased flow-mediated vasodilation was associated
with the reduction of UA levels (Maxwell et al. 2001).
In summary, experimental evidence suggest a complex but potentially direct causal
relationship between serum UA and numerous deleterious biologic functions involved
in the pathogenesis of metabolic syndrome and atherosclerosis (Kang et al. 2002;
Mazzali et al. 2001; Mazzali et al. 2002; Watanabe et al. 2002). For example, in in
vitro studies UA stimulates both vascular smooth muscle cell proliferation and the
release of chemotactic and inflammatory substances (Mazzali et al. 2002; Rao et al.
1991; Watanabe et al. 2002), induces monocyte chemotaxis (Zare et al. 2006), inhibits
endothelial cell proliferation and migration (Kang et al. 2005; Khosla et al. 2005), and
causes oxidative stress in adipocytes resulting in the impaired secretion of adiponectin
(Sautin et al. 2007). The role of serum UA in development of metabolic abnormalities
is summarized in Table 4.
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Table 4 Hyperuricemia possible roles in the metabolic syndrome and cardiovascular diseases
Components Potential mechanisms
Hypertension 1. Urate reabsorption increased in setting of increased renal vascular
resistance, microvascular disease predisposes to tissue ischemia that
leads to increased urate generation (excess purine metabolism) and
reduced excretion (due to lactate competing with urate transporter in the
proximal tubule)
2. Increased oxidative – redox stress
3. Antioxidant – Prooxidant Paradox:Urate Redox Shuttle
4. UA effect on the renin-angiotensin system.
Obesity – Insulin
resistance
1. Overproduction of UA and impairment in renal clearance of UA
2. Leptin may induce hyperuricemia.
3. Insulin increases sodium reabsorption and is tightly linked to urate
reabsorption.
Glucose intolerance
and/or Diabetes
Acting through obesity and insulin resistance.
Dyslipidaemia Link between fatty acid synthesis and production of NADPH.
Accelerated
atherosclerosis
1. Endothelial dysfunction
2. Accelerated atherosclerosis with increased vascular cell apoptosis
3. Inflammatory necrosis with increased purine metabolism resulting in
hyperuricemia
4. Increased oxidative stress through ischemia-reperfusion and xanthine
oxidase
5. Antioxidant – Prooxidant Paradox: Urate Redox Shuttle
6. UA effect on the renin-angiotensin system.
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3 AIMS OF THIS STUDY
Our overall aims were to study the prevalence of hyperuricemia and the metabolic
factors clustering with hyperuricemia, to explore the dynamical changes in blood UA
levels with the deterioration in glucose metabolism and to estimate the predictive
capability of UA in the development of diabetes.
The specific objectives of the study are:
1. To determine the prevalence of hyperuricemia and gout and the risk factors
associated with hyperuricemia in Chinese population in an urban community in
Qingdao, China (Study I).
2. To explore the association of serum UA levels with the metabolic abnormalities
based on cross-sectional data in non-diabetic subjects of Indian and Creole
living in Mauritius, and in Chinese living in Qingdao (Study II)
3. To estimate the association between FPG, 2-hPG levels and serum UA
concentrations in a Chinese adult population (Study III).
4. To investigate the predictive value of baseline blood UA for the development of
diabetes  in  Asian  Indians  and  Creoles  living  in  Mauritius  (Study  IV).
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4 POPULATIONS AND METHODS
4.1 Study Populations
Qingdao Diabetes Survey (QDS)-2001
A stratified, random cluster sampling method was used to select a representative
sample of the general population aged 20-74 years in Qingdao in April-June, 2001 and
in April-May, 2002. Street blocks were randomly drawn from rural and urban
communities to serve as clusters for the survey. From each selected block, families
were randomly selected, and a total of 12 210 subjects who had lived in Qingdao for at
least 5 years were invited to take part in the survey (Figure 2).
Figure 2. The sampling procedure and the participation rate in the survey in Qingdao, China, in
               2001-2002.
Random population sample
(N = 12 210)
Direct 75g oral glucose
tolerance test (OGTT) in
April-May, 2002 (N = 2 777)
Two-step screening approach in
April-June, 2001 (N = 9 433)
2 438 attended OGTT
(response rate 87.8%)
7 820 attended fasting capillary
glucose (response rate 82.9%)
1 610 qualified
for data analysis
for Paper II
Subjects qualified for data analyses according to inclusion criteria
Paper I (N = 2 023), Paper II (N = 3 632), Paper III (N = 1 156)
443 Undiagnosed diabetes by
criteria of fasting plasma glucose
? 7.0 mmol/l
1 645 with fasting capillary
glucose ? 6.1mmol/l were invited
to OGTT (response rate 97.5%)197 Undiagnosed
diabetes by criteria
of fasting plasma
glucose ? 7.0
mmol/l and/or 2-h
plasma glucose
? 11.1 mmol/l
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Two screening strategies for diabetes were applied. In April-June, 2001, a two-step
screening strategy was applied to the target populations (n = 9 433). A fasting capillary
whole blood glucose (FCG) test was first administrated to all participants between
7:00-9:30 in the morning. The participation rate for the FCG test was 82.9%. A total of
1 645 subjects who had a FCG value of ? 6.1mmol/l were further invited to a standard
75g 2-hour oral glucose tolerance test (OGTT); 1 610 subjects with complete data for
the data analysis were included in the Study III.
In April-May, 2002, a total of 2 777 eligible subjects were invited to take part a
standard OGTT directly in an urban community, Zhanshan. Of these, 2 438 (903 men
and 1 535 women) participated, with an overall response rate of 87.8%. Among
participants in Zhanshan community, 415 subjects were excluded due to missing data
on glucose or other lab measurements, leaving 2 023 subjects in the data analysis for
Study I and 1 156 non-diabetic subjects free of hypertension and cardiovascular
diseases for Study II. A total of 3 632 (1 288 men and 2 344 women) subjects with data
on both FPG and serum UA were included in the current data analysis for the
association of serum UA and plasma glucose (Study III), after further excluded those
with a previous history of physician diagnosed gout.
Mauritius 1987, 1992 and 1998 Non-Communicable Diseases Surveys (MNCDS)
The  population  of  Mauritius  consists  of  70%  Asian  Indians  (both  Hindus  and
Muslims), 28% Creoles (predominantly African ancestry), and 2% Chinese, with
varying amount of European, Malagasy and Indian admixture (Central Intelligence
Agency. 2003). Population based surveys for prevention and control of chronic non-
communicable diseases were undertaken in 1987, 1992, and 1998. Details of the
survey methodology have been published previously (Dowse et al. 1995; Soderberg et
al. 2005).
In 1987, 10 randomly selected (with probability proportional to size) population
clusters were examined, and all eligible residents were invited to participate. In both
1992 and 1998, all previous participants were invited, plus all other current eligible
residents in each cluster and with three new clusters added in 1992. Briefly, all
residents aged 25-74 years in randomly selected population clusters were invited to
participate (Soderberg et al. 2005). The response rate was 86 %, 90 %, 87 %,
respectively, in the 1987, 1992, and 1998 survey. The numbers of Mauritian Indian and
Mauritian Creole who attended baseline surveys were 4 661 in 1987, 2 638 in 1992,
and 1 440 in 1998. The following groups of participants were excluded: 193
participants with missing data on the measurements required for the current data
analysis, 1 161 participants with a personal history of hypertension, gout and
cardiovascular diseases including coronary heart disease, stroke, peripheral vascular
disease, 1 178 individuals with known or newly diagnosed diabetes. Therefore, a total
of 6 207 subjects (2 867 men) of Mauritian Indian and Mauritian Creole were included
in the data analysis for the association of serum UA with metabolic risk factors in
Study II.
Individuals participating in the study in 1987 or 1992 were invited to attend re-
examination in 1992 and/or 1998 using the same study protocol. According to the date
of entering (free of diabetes) and the date of exiting (developed diabetes) the study,
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participants were divided into four sub-cohorts: 1987 to 1992, 1987 to 1998, 1987
through 1992 to 1998, and 1992 to 1998. Among 5083 individuals who were free of
diabetes in the 1987 baseline survey, 22.5 % attended the re-examination in 1992,
3.5 % in 1998, 51.7 % both in 1992 and 1998, which gave an overall follow-up rate of
77.7 %. Among 2845 individuals who were free of diabetes in the 1992 baseline survey,
60.6 % attended the re-examination in 1998 (Nyamdorj et al. 2008). A total of 1 941
men (1 409 Indians, 532 Creoles) and 2 318 non-pregnant women (1 645 Indians, 673
Creoles) aged 25-74 years at baseline qualified for studying the incidence of diabetes
(Study  IV).  The  inclusion  criteria  for  Study  IV  were:  (1)  UA  determined  at  both
baseline and follow-up survey, (2) data on BMI, systolic and diastolic blood pressure,
fasting and 2h plasma glucose, serum lipids, creatinine, smoking and alcohol
consumption at baseline, and (3) free of diabetes, cardiovascular diseases, renal failure
and gout at baseline.
The  demographic,  clinical  and  metabolic  characteristic  of  the  study  population  in
general are summarized in Table 5. For all these studies, informed consent was
obtained  from  all  participants  in  each  of  the  surveys,  and  the  survey  protocols  were
reviewed and approved by each of the local ethics committees (Melbourne, Australia
and Qingdao, China).
Table 5 Characteristics of the study population in Mauritius and in Qingdao, China
Men
Mauritian Indian Mauritian Creole Chinese
Baseline survey (year) 1987 1992 1998 1987 1992 1998 2001* 2002
Total Number 1 517 842 354 571 347 153 568 720
Undiagnosed diabetes (%) 141 (9.3) 81 (9.6) 46 (13.0) 41 (7.2) 38 (11.0) 12 (7.8) 90 (15,8) 57 (7.9)
Age (years) 42 (13) 43 (12) 43 (11) 44 (13) 44 (12) 43 (12) 52 (12) 53 (12)
Waist circumference (cm) 77.8 (9.2) 86.5 (8.8) 88.0 (10,6) 77.2 (8.9) 85.5 (9.7) 85.1 (11.8) 92.0 (9.3) 90.0 (9.5)
Body mass index (kg/m2) 22.7 (3.7) 24.0 (3.8) 24.5 (4,1) 22.8 (3.5) 24.1 (4.2) 24.0 (4.6) 26.3 (3.6) 26.4 (3.4)
Systolic blood pressure (mmHg) 126 (18) 122 (18) 125 (20) 133 (21) 127 (19) 126 (19) 133 (21) 129 (19)
Diastolic blood pressure (mmHg) 79 (12) 75 (12) 76 (14) 82 (13) 79 (13) 75 (13) 86 (13) 85 (11)
Fasting plasma glucose (mmol/l) 5.7 (2.0) 6.1 (2.0) 6.4 (2,3) 5.7 (1.5) 6.1 (2.1) 6.5 (2.8) 7.1 (3.5) 5.7 (1.7)
2h plasma glucose (mmol/) 6.9 (3.5) 7.3 (4.0) 7.4 (4,0) 6.5 (2.9) 6.7 (3.1) 7.1 (4.4) 9.6 (5.9) 6.7 (3.9)
Triglycerides (mmol/l) 1.8 (1.3) 1.6 (1.1) 1.7 (1,0) 1.7 (1.4) 1.6 (1.0) 1.7 (1.0) 1.7 (1.5) 1.8 (1.5)
Total cholesterol (mmol/l) 5.6 (1.6) 4.9 (0.8) 5.1 (1,1) 5.7 (1.8) 4.9 (0.9) 5.1 (1.2) 5.4 (1.2) 5.6 (1.2)
HDL-cholesterol  (mmol/l) 1.3 (0.4) 1.2 (0.3) 0.9 (0,3) 1.3 (0.4) 1.3 (0.4) 1.0 (0.39 1.56 (0.52) 1.49 (0.28)
Serum uric acid (?mol/l) 398 (84) 362 (84) 351 (79) 399 (86) 368 (90) 366 (83) 363 (98) 390 (89)
Creatinine (?mol/l) 85 (31) 110 (46) 99 (229 85 (16) 111 (20) 99 (12) NA NA
Current smokers (%) 863 (56.9) 400 (47.5) 153 (43.2) 380 (66.5) 194 (55.9) 83 (54.2) 308 (54.3) 326 (45.3)
Current drinkers (%) 1 134 (74.8) 455 (54.0) 200 (56.5) 496 (86.9) 263 (75.8) 123 (80.4) 261 (46.0) 300 (41.7)
Follow-up Yes Yes No Yes Yes No No No
*Among subjects who with fasting capillary glucose ?6.1mmol/l at the first step screening. Data are crude mean (SD) and number (percentage)
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Table 5 Continues
Women Mauritian Indian Mauritian Creole Chinese
Baseline survey (year) 1987 1992 1998 1987 1992 1998 2001* 2002
Total Number 1 688 956 435 727 441 195 1 042 1 302
Undiagnosed diabetes (%) 119 (7.0) 77 (8.1) 38 (8.7) 72 (9.9) 34 (7.7) 22 (11.3) 210 (20.2) 86 (6.6)
Age (years) 42 (13) 43 (12) 43 (11) 45 (14) 46 (13) 42 (12) 54 (11) 52 (12)
Waist circumference (cm) 74.0 (11.4) 83.9 (11.4) 78.1 (10.6) 77.6 (11.9) 84.6 (10.8) 81.7 (12.4) 87.3 (10.3) 83.5 (9.9)
Body mass index (kg/m2) 23.9 (4.7) 25.6 (5.2) 25.2 (4.8) 24.9 (5.0) 26.7 (5.3) 26.9 (5.9) 26.6 (4.0) 26.1 (3.8)
Systolic blood pressure (mmHg) 122 (19) 121 (19) 121 (21) 133 (24) 129 (25) 125 (22) 135 (24) 128 (21)
Diastolic blood pressure (mmHg) 74 (11) 73 (12) 71 (12) 79 (13) 79 (15) 73 (13) 84 (11) 82 (11)
Fasting plasma glucose (mmol/l) 5.6 (1.9) 6.2 (2.6) 5.9 (2.0) 6.0 (2.2) 6.1 (2.4) 5.9 (2.2) 7.2 (3.7) 5.7 (1.8)
2h plasma glucose (mmol/l) 7.4 (3.4) 7.5 (3.4) 7.4 (3.0) 7.6 (3.4) 7.4 (3.2) 7.0 (2.7) 9.5 (5.8) 6.5 (3.3)
Triglycerides (mmol/l) 1.3 (0.9) 1.3 (0.7) 1.2 (0.6) 1.3 (0.8) 1.3 (0.7) 1.2 (0.6) 1.6 (1.1) 1.5 (0.9)
Total cholesterol (mmol/l) 5.3 (1.5) 4.8 (0.9) 4.7 (1.1) 5.8 (1.8) 5.0 (0.9) 4.6 (1.1) 5.5 (1.2) 5.7 (1.1)
HDL-cholesterol  (mmol/l) 1.3 (0.3) 1.3 (0.3) 1.0 (0.3) 1.3 (0.3) 1.4 (0.3) 1.0 (0.3) 1.67 (0.55) 1.52 (0.28)
Uric acid (?mol/l) 305 (73) 275 (76) 258 (68) 318 (80) 294 (77) 290 (70) 298 (83) 316 (70)
Creatinine (?mol/l) 67 (19) 85 (41) 77 (15) 69 (13) 90 (44) 78 (10) NA NA
Current smokers (%) 37 (2.2) 6 (0.6 ) 1 (0.2) 138 (19.0)  54 (12.2) 20 (10.3) 202 (19.4) 46 (1.2)
Current drinkers (%) 620 (36.7)  178 (18.6)  66 (15.2)  484 (66.6)  192 (43.5)  92 (47.2) 56 (5.4) 21 (1.6)
Follow-up Yes Yes No Yes Yes No No No
*Among subjects who with fasting capillary glucose ?6.1mmol/l at the first step screening. Data are crude mean (SD) and number (percentage)
4.2 Survey procedures and physical examinations
The QDS was conducted during the months of April to June in 2001 and April to May
in 2002. The survey team consisted of nurses and physicians, who were trained for one
week before the fieldwork. Nurses distributed survey questionnaires to all participants
during a house visit. The questionnaire contained questions on demographic, dietary,
drinking and smoking information, personal and family history of diabetes, gout and
hyperuricemia, previous history of hypertension, cardiovaslular disease and
dyslipdemia. A participant was classified as an alcohol drinker if he/she currently
drank beer, wine, or liquors during the last half a year.
Height  and  weight  was  measured  with  light  clothes  and  without  shoes.  BMI  was
calculated by dividing the weight (kg) by the height (m) squared. Waist circumference
at the mid-point between the lower margin of rib and the iliac crest, and hip
circumference at the maximal horizontal girth between the waist and thigh were
measured. The measurements were made to the nearest 0.5 cm. Two consecutive
measurements were performed, and if the variation was greater than 2.0 cm between
the two readings, a third measurement was taken. The two most consistent readings
were  used  in  the  analysis.  Waist  to  hip  ratio  was  calculated  by  waist  circumference
divided by hip circumference. Three consecutive BP readings, at least 5 min apart,
were taken from the right arm of seated subjects and the average of the three readings
was used in data analysis.
The survey methodology was similar in all three MNCDS in 1987, 1992, and 1998. All
eligible adults were asked to attend a survey site during 8:00-10:00 A.M. after an
overnight fast. After registration, local nurses trained for the survey administered a
questionnaire and measured anthropometric parameters (Soderberg et al. 2005).
Ethnicity was determined by self-report. Menstruation information was collected in the
follow-up surveys. Pregnancy status was determined based on a self-reported
pregnancy history. Every participant was asked whether or not anyone of first or
second relatives in his/her family ever had diabetes. If the answer was yes, the family
history of diabetes was considered positive.
Waist circumference was measured twice at the midpoint between the lower margin of
the ribs and the iliac crest to the nearest 0.5 cm. The third measurement was taken if
the first two readings were different, greater than 2 cm. The mean of the closest two
measurements was used to calculate waist circumference. Hip circumference was
measured as the maximum circumference around the buttocks posteriorly and
symphysis pubis anteriorly by viewing it from the side. BMI was calculated by
dividing the weight (kg) by the height (m) squared. BP was measured twice on the
right arm of the participant with elbow level at heart, after sitting for five to ten
minutes using a standard mercury sphygmomanometer, using the first and fifth
Korotkoff  sounds  to  the  nearest  2  mmHg.  The  mean  of  the  two  measurements  was
used in data analysis. Personal history of hypertension was based on self-reported use
of antihypertensive drugs. Information on smoking and alcohol drinking were obtained
by interview.
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4.3 Laboratory methods
In the QDS, Individuals were instructed to fast for at least 10 hours before the blood
was drawn. Blood samples were collected at the local community health clinic. Fasting
blood specimens were collected for measurement of serum UA, plasma glucose, serum
total cholesterol, triglycerides, and HDL-C. After fasting blood sample was drawn,
each participant was asked to drink 75g glucose dissolved in 300 ml water (World
Health Organisation 1999) between 7:00-9:30 A.M. Venous blood samples were
collected from the antecubital vein into a vacuum tube containing sodium fluoride
before  and  120  min  after  the  ingestion  of  75g  glucose.  The  specimens  were  put  into
ice-cooled containers and transported immediately to clinical laboratory of the
Qingdao Endocrine and Diabetes Hospital. The plasma glucose was determined by
glucose oxidase method within 3 hours after the blood sample was collected. Serum
was frozen at –20°C and serum UA was measured by the uricase method within a
month in the same clinical laboratory. Fasting serum lipid profile, including
triglycerides, total, HDL-C was determined by the enzymatic method.
In the MNCDS, participants not taking antidiabetic drugs were examined with a 75g
OGTT. Plasma glucose concentrations were measured immediately after the blood
sampling at the survey site using Yellow Springs Instruments (YSI, OH, USA) glucose
analyzers in both 1987 and 1992. In 1998, plasma was frozen immediately and glucose
was measured approximately 4 months later in Newcastle upon Tyne, UK, using the
YSI glucose analyzers. Considering the delay in analysis, the glucose concentrations of
1998 values were adjusted upwards using an equation (adjusted glucose = 0.0288 +
1.037 × measured glucose) based on the difference between on-site values and quality
controls from the 1987 and 1992 surveys (Soderberg et al. 2005). Fasting and 2-h
serum insulin was measured in Newcastle upon Tyne, UK. A modified
radioimmunoassay method proposed by Soeldner and Slone (Soeldner et al. 1965) was
used. The interassay and intraassay coefficients of variation were 6% and 4%,
respectively. Cross reactivity with intact proinsulin and 32,33-split proinsulin was 27%
and 16%, respectively (Soderberg et al. 2007). The homeostasis model assessment of
IR (HOMA-IR) was calculated as fasting serum insulin (?U/ml) x FPG (mmol/l)/22.5
and  was  used  as  an  index  of  IR.  UA,  triglycerides,  total  cholesterol,  and  HDL-C
concentrations were measured at a central laboratory, in Mauritius, in fresh heparin
plasma (1987) and serum (1992 and 1998). In 1987, manual enzymatic methods were
used, but in 1992 and in 1998 a Chemistry Profile Analyser Model LS (Coultronics,
Port Louis, Mauritius) was used. For quality assessment, every 10th sample was also
analyzed in Newcastle upon Tyne, UK. On the basis of the external quality assurance
data, total cholesterol and triglycerides were adjusted downwards by using calculated
regression equations (Dowse et al. 1995), while uncorrected HDL-C and UA were used
here as quality controls showed similar results.
4.4 Definitions
Hyperuricemia
Hyperuricemia was defined as serum UA > 420 ?mol/l for men and > 360 ?mol/l for
women according to the common guidelines (Fang et al. 2000). The diagnosis of gout
was based on self-reported information that was confirmed by reading the patients'
hospital diagnosis record (in Qingdao, China) or clinic record (in Mauritius).
Diabetes
Diabetes was determined according to WHO/IDF 2006 criteria (World Health
Organisation/International Diabetes Federation 2006). Known diabetes was diagnosed
if  participants  reported  a  history  of  a  physician  diagnosis  of  diabetes  and  was  either
taking hypoglycemic medication, or the FPG level of ? 7.0 mmol/l and/or the 2-hPG
value of ? 11.1 mmol/l at the survey. Newly diagnosed diabetes was diagnosed if one
of these glucose values exceeded the above cut-off points and there was no a prior
history of diabetes. Participants without known diabetes were divided into glucose
categories according to either FPG or 2-hPG distributions. Both known and newly
diagnosed diabetic individuals at the baseline survey were excluded from the current
data analysis on the prediction of UA for incident diabetes. Incident cases of diabetes
were identified at the end of follow-up among those who were free of diabetes at
baseline.  Subjects  with  a  FPG of  <  7.0  mmol/l  but  a  2-hPG of  7.8-11.0  mmol/l  were
defined as having IGT; those with a FPG of 6.1-6.9 mmol/l but a 2-hPG of
< 11.1 mmol/l were categorized as having IFG.
Metabolic abnormalities
Taking into account the differences both chronologically and methodologically
between studies, metabolic syndrome variables were categorized into sex-, ethnic- and
cohort-specific quintiles. We defined the top quintile of waist circumference, BMI, BP,
triglycerides, total cholesterol and glucose levels, and the bottom quintile of HDL-C as
abnormal. Elevated BP was defined as either systolic or diastolic BP in the top quintile
distributions. Hyperuricemia was defined as top quintile of UA values in each cohort in
data analysis (Study II).
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4.5 Statistical analyses
The standard world population for 10-year intervals was adopted to calculate age-
standardized prevalence of hyperuricemia and self-reported gout (Waterhouse 1976).
Analysis  of  covariance  was  used  for  comparison  of  the  differences  in  continuous
variables between subgroups in the Qingdao data, a general linear model adjusting for
age, ethnicity and cohort for continuous variables in the Mauritius data, and Chi-square
test for categorical variables were used to compare the differences between subgroups.
Serum triglycerides, FPG, 2hPG, fasting and 2h insulin were log10-transformed to
reduce skewness and geometric means were reported. The multiple linear regression
analysis was applied to study the association of serum UA with other related variables
for men and women (Study I, III), separately. The log-likelihood ratio test was
performed to compare the association of each of the metabolic syndrome variables
with hyperuricemia (Study II). SPSS package (Chicago, IL) for Windows version 14.0
was used. A p-value of < 0.05 (two-tailed) was considered statistically significant in all
analyses.
In Mauritius data, taking into account the differences between cohorts both
chronologically and methodologically, sex-, ethnicity- and cohort-specific standard
deviation (SD) of continuous variables and their Z scores were calculated and fitted
into the models. Cox proportional hazards model for an interval censored survival
analysis using the ‘interval censoring’ package in R 2.2.4 program (http://www.r-
project.org/) was fitted to estimate the hazard ratios and their 95% CIs for the
incidence of diabetes corresponding to a one SD increase in UA concentration at
baseline, using age as time scale (Study IV). Except for the pooled analysis, meta-
analysis using the method detailed by Fleiss (Fleiss 1993) was also performed based
on  individual  cohort  data  (Study  II).  Individual  ?-coefficients  for  each  cohort  and
combined ?-coefficients for all cohorts with three or more metabolic syndrome related
disorders vs. fewer than three factors, corresponding to a one SD increase in serum UA
concentration, were calculated and reported. Q statistic for measuring study-to-study
variation in effect size was performed. Since Q was not statistically different from zero
(Q = 0.38 for Indian men and Q = 2.96 for Creole men, and Q = 3.35 and Q = 0.89, for
Indian and Creole women, respectively, with 2 df all p > 0.10), fixed effect approach
was chosen.
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5 RESULTS
5.1 The prevalence of hyperuricemia and its risk factors in Chinese populations
in 2002 (Study I)
Age-adjusted mean serum UA (389 ?mol/l for men and 316 ?mol/l for women),
triglycerides (1.76 mmol/l for men and 1.45 mmol/l for women), waist circumference
(89.9 cm for men and 83.6 for women) and waist to hip ratio (0.90 for men and 0.84
for women) were significantly higher in men (n = 720) than in women (n = 1 302) (all
p < 0.05). A total of 215 men and 294 women were found with hyperuricemia in the
survey in 2002 in Qingdao. The crude prevalence of hyperuricemia was 29.9% (95%
CI 26.6-33.2) for men and 22.6% (95% CI 20.4-25.0) for women. The age-
standardized prevalence of hyperuricemia was 25.3% (95% CI 23.5-27.2) in the adult
population aged 20-74 years. It was higher in men than women below age 55 years (p
< 0.001), but no sex difference was observed above age 55 years. Postmenopausal
women had a much higher prevalence of hyperuricemia compared to premenopausal
women (29.1% vs. 15.4%, p<0.001). There were 11 gout patients. The mean UA
among them was higher than that for subjects without gout (416.1 ?mol/l vs. 341.6
?mol/l, p = 0.004). The age-standardized prevalence of gout was 0.63% (95% CI 0.05-
1.21) in men, 0.23% (95% CI 0.0-0.49) in women and 0.36 % (95% CI 0.10-0.62) in
the total study population.
In multivariate regression analysis, BMI, triglycerides, and alcohol drinking, with
standardized ?-coefficient of 0.23, 0.23, and 0.10, respectively, were significantly and
positively associated with increase in serum UA concentration in men, explaining
15.0% of the variation in serum UA. In women, BMI, triglycerides, total cholesterol,
and systolic BP were positively, whereas FPG negatively associated with the serum
UA levels, with standardized ?-coefficient of 0.17, 0.18, 0.05, 0.08, and -0.05,
respectively, which explained 11.0% of serum UA variations. Systolic and diastolic BP,
and hypertension was found to have significant direct correlation with UA.
5.2 Mean UA levels in Mauritian populations in 1987, 1992 and 1998
(unpublished data)
The prevalence (95% CI) of hyperuricemia defined as UA > 420 ?mol/l for men and
UA > 360 ?mol/l for women was 36.0% (33.7-38.3), 20.4% (17.7-23.1) and 20.3
(16.1-24.5) for men and 18.2 (16.5-19.9), 9.3 (7.5-11.1) and 4.3 (2.5-6.1) for women in
1987, 1992 and 1998, respectively. Since the laboratory measures differ between
surveys, a direct comparison between cohorts can not be made. To make the data
comparable, cohort- and sex-specific Z scores of UAs were calculated. The UA levels
escalated from the year 1987 to 1992 then to 1998 in Mauritian Creole men and
women, with the trend p value of 0.04 and 0.03, respectively, but not in Mauritian
Indian men and women (Table 6).
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5.3 Association of UA with metabolic abnormalities (Study II)
Hyperuricemia (defined as top quintile of UA values in each cohort) and
metabolic risk factors
In multivariate regression analysis, the association of hyperuricemia with each of the
metabolic risk factors was estimated and compared using the log-likelihood ratio test.
Waist circumference, BMI, and triglycerides were statistically strongly associated with
hyperuricemia in all groups except in Chinese women, in whom triglycerides, HDL-C,
and total cholesterol were associated with hyperuricemia. Adding creatinine to the
model did not change the association of hyperuricemia with waist circumference, BMI,
triglycerides, HDL-C, total cholesterol, and BP, although creatinine by itself associated
with hyperuricemia in both Indians and Creoles (p < 0.05).
UA and metabolic syndrome components
Prevalence  (95%  CI)  of  a  cluster  of  three  or  more  metabolic  disorders  was  9.6%
(8.3-10.9), 9.4% (7.4-11.4) and 12.0% (8.9-15.1) for Indian, Creole and Chinese men,
and 10.5% (9.3-11.7), 10.1% (8.2-12.0) and 13.0% (10.6-15.4) for women,
respectively. The prevalences did not differ significantly between Mauritian Indians,
Creoles and mainland Chinese in either sex (p > 0.05 for both).
Multivariate  adjusted  odds  ratios  (95%  CIs)  for  with  three  or  more  metabolic
syndrome related disorders vs. fewer than three factors, corresponding to a one SD
increase in UA concentration were 1.75 (1.51 to 2.02), 2.19 (1.71 to 2.82) and 2.30
Table 6 Cohort- and sex-specific mean Z-score of uric acid (95% CI) in Mauritian Indian and
Creole populations
Cohort Mauritian Indian Mauritian Creole
Men N Mean (95% CI) N Mean (95% CI)
1987 1186 0.02 (-0.04, 0.08) 452 -0.05 (-0.15, 0.04)
1992 619 0.00 (-0.08, 0.08) 260 0.01 (-0.12, 0.13)
1998 245 -0.08 (-0.20, 0.05) 105 0.18 (-0.02, 0.37)
p value for trend 0.20 0.04
Women
1987 1364 -0.04 (-0.09, 0.02) 511 0.10 (0.01, 0.18)
1992 677 -0.08 (-0.15, -0.01) 323 0.17 (0.06, 0.28)
1998 327 -0.13 (-0.24, -0.03) 138 0.32 (0.15, 0.49)
p value for trend 0.09 0.03
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(1.68 to 3.16) in Indian, Creole and Chinese men, and 1.74 (1.52 to 2.00), 1.75 (1.40 to
2.19) and 1.72 (1.37 to 2.16) in women, respectively, after adjustment for age, cohort,
smoking and alcohol consumption. These associations remained statistically significant
after further adjustment for BMI (Figure 3 B1 and B2) or both BMI and waist
circumference simultaneously in the same model, with odds ratios (95% CIs) of 1.39
(1.18 to 1.63), 1.59 (1.23 to 2.07) and 1.76 (1.23 to 2.53) in Indian, Creole and Chinese
men, and 1.29 (1.11 to 1.49), 1.39 (1.10 to 1.76) and 1.63 (1.27 to 2.09) in women.
Figure 3. Beta coefficients (black square) and 95% CIs (bar) for with three or more metabolic
syndrome variables of waist circumference, elevated blood pressure, fasting glucose,
triglycerides and high density lipoprotein cholesterol vs. fewer than three factors,
corresponding to a one SD increase in serum uric acid in: (A) men without (A1) and with (A2)
body mass index adjustment; and in (B) women without (B1) and with (B2) body mass index
adjustment
A1
-1 0 1 2 3
Beta coefficient (95% CI)
All Mauritian Indian
Qingdao Chinese 2002
Mauritian Indian1987
Mauritian Indian1992
Mauritian Indian1998
Mauritian Creole1987
Mauritian Creole1992
Mauritian Creole1998
All Mauritian Creole
A2
-1 0 1 2 3
Beta coefficient (95% CI)
All Mauritian Indian
Qingdao Chinese 2002
Mauritian Indian1987
Mauritian Indian1992
Mauritian Indian1998
Mauritian Creole1987
Mauritian Creole1992
Mauritian Creole1998
All Mauritian Creole
B1
-1 0 1 2 3
Beta coefficient (95% CI)
All Mauritian Indian
Qingdao Chinese 2002
Mauritian Indian1987
Mauritian Indian1992
Mauritian Indian1998
Mauritian Creole1987
Mauritian Creole1992
Mauritian Creole1998
All Mauritian Creole
B2
-1 0 1 2 3
Beta coefficient (95% CI)
All Mauritian Indian
Qingdao Chinese 2002
Mauritian Indian1987
Mauritian Indian1992
Mauritian Indian1998
Mauritian Creole1987
Mauritian Creole1992
Mauritian Creole1998
All Mauritian Creole
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5.4 Association of UA with plasma glucose (Study III, IV)
5.4.1 The pattern of changes in serum UA levels with plasma glucose in Chinese
population (cross-sectional study, Study III)
There was an increasing trend in serum UA concentration when the levels of FPG
increased from low to high up to the FPG level of 7.0mmol/l; thereafter, the UA
concentration started to decrease with further increases in FPG levels (Figure 4A).
After multivariate adjustments for age, residential areas, BMI, and triglycerides, the
increasing trend in UA at the low FPG level (< 7.0 mmol/l) leveled off in men, but still
remained in women (Figure 4B). The declining trend of UA at the higher FPG
concentration remained significant after further adjusting for the previous disease
history of hypertension, cardiovascular disease, and dyslipidemia in both genders, with
a ? value of -0.26 in men and -0.20 in women (p < 0.01) (Figure 4C).
The lowest UA level appeared in subjects with the highest FPG concentrations
?? 10 0 mmol/l) in previously undiagnosed diabetic men and women (p < 0.001).
Adjustment for BP or a history of hypertension did not alter the observed relationship.
A decreasing trend of serum UA levels with increasing 2-hPG at range of
2-hPG ? 8.0mmol/l approximately was also observed, with a multivariate adjusted ?
coefficient of -0.13 (p < 0.05) in men and -0.15 in women (p < 0.001). We did not,
however, observe an upward positive relationship between UA and 2-hPG in the low
2-hPG range.
49
n (men)      142      483      221     169       56        43         47         64          56
n (women)  231     890      442      314      121       66      109          90          77
Figure 4A
n (men)     142    483      221     169        56        43          47        64          56
n (women)  231   890     442      314      121        66         109       90          77
Figure 4B
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Figure 4. Mean serum uric acid (?mol/l) and their 95% confidence intervals (bar) in men (solid
line) and women (dashed line) according to fasting plasma glucose categories, after adjustment for
age and resident areas (A); additional adjustment for body mass index and triglycerides (B); and
further adjustment for previous history of hypertension, cardiovascular disease, and dislipidemia
(C).
n (men)      142    483      221      169       56       43         47        64          56
n (women)  231    890     442       314     121      66        109        90          77
Figure 4C
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5.4.2 Baseline UA predicted the development of diabetes during the follow-up in
Mauritian populations (Study IV)
Changes in UA with the development of incident diabetes
A total of 337 (17.4%) men (252 Indians and 85 Creoles) and 379 (16.4%) women
(257 Indians and 122 Creoles) were diagnosed with diabetes at the end of the follow-
up. The incidence of diabetes did not differ significantly between Mauritian Indians
and Creoles in either sex (p > 0.05 for both).
Baseline UA levels were significant higher in individuals with incident diabetes
(423 ?mol/l in men and 311 ?mol/l in women) than in those who retained free of
diabetes  at  the  end  of  the  follow-up  (384  ?mol/l  in  men  and  292  ?mol/l  in  women).
Regarding to the difference between cohorts both chronologically and
methodologically, Z scores of blood UA and other measures of interest at both baseline
and follow-up were used in the following data analyses. The UA levels fell
significantly from baseline to follow-up in the men (0.35 to 0.02) and the
pre-menopausal women (0.04 to -0.21) who developed diabetes (p < 0.001 for both),
but not in the post-menopausal women (0.38 to 0.45).
High UA at baseline predicted incident diabetes
Multivariate adjusted hazard ratios for the incidence of diabetes corresponding to a one
SD increase in UA at baseline in Indians, Creoles and both combined were 1.32, 1.62
and 1.40 in men, and 1.26, 1.20 and 1.23 in women, respectively, after adjusting for
FPG, serum creatinine, alcohol consumption, history of hypertension, family history of
diabetes, and cohort (Table 7). Further adjustment for BMI, triglycerides, and fasting
insulin attenuated the risk related to the baseline UA in both men and women, but the
hazard ratios still remained statistically significant in Mauritian Indians and Creoles in
men. Replacing BMI, history of hypertension, triglycerides, fasting insulin, and FPG
with  waist  circumference,  systolic  or  diastolic  BP,  HDL-C  or  total  cholesterol,
HOMA-IR, and 2-hPG, did not change the results substantially. Adjustment for the
baseline smoking consumption did not alter the relationships observed between UA
and diabetes  either.  In  those  postmenopausal  women at  the  end  of  the  follow-up,  the
findings were consistent with that for premenopausal women.
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Table 7 Hazard ratios (95% CI) for diabetes incidence corresponding to a one SD increase in covariates
at baseline (Study IV)
Mauritian Indian Mauritian Creole Total
(n, case) (n, case) (n, case)
Men (1409, 252) (532, 85) (1941, 337)
   Model 1
      Uric acid (?mol/l) 1.32 (1.18, 1.49) 1.62 (1.34, 1.96) 1.40 (1.27, 1.55)
      Fasting plasma glucose (mmol/l) 1.99 (1.80, 2.20) 1.50 (1.25, 1.79) 1.82 (1.68, 1.98)
   Model 2
      Uric acid (?mol/l) 1.14 (1.01, 1.30) 1.37 (1.11, 1.68) 1.19 (1.07, 1.34)
      Body mass index (kg/m2) 1.41 (1.26, 1.58) 1.69 (1.40, 2.05) 1.46 (1.32, 1.61)
      Triglycerides (mmol/l) 1.14 (1.03, 1.27) 1.35 (1.14, 1.59) 1.18 (1.08, 1.28)
       Fasting plasma glucose (mmol/l) 1.97 (1.79, 2.17) 1.53 (1.27, 1.82) 1.81 (1.66, 1.96)
Women (1645, 257) (673, 122) (2318, 379)
   Model 1
      Uric acid (?mol/l) 1.26 (1.13, 1.40) 1.20 (1.02, 1.41) 1.23 (1.13, 1.35)
      Fasting plasma glucose (mmol/l) 1.99 (1.85, 2.14) 1.79 (1.58, 2.03) 1.92 (1.80, 2.06)
   Model 2
      Uric acid (?mol/l) 1.07 (0.95, 1.22) 1.01 (0.84, 1.22) 1.05 (0.95, 1.16)
      Body mass index (kg/m2) 1.32 (1.17, 1.49) 1.33 (1.12, 1.58) 1.32 (1.19, 1.45)
      Triglycerides (mmol/l) 1.27 (1.14, 1.41) 1.32 (1.15, 1.52) 1.27 (1.17, 1.38)
       Fasting plasma glucose (mmol/l) 1.92 (1.77, 2.09) 1.71 (1.50, 1.96) 1.86 (1.73, 2.00)
Model 1 adjusted for cohort, serum creatinine, alcohol consumption, history of hypertension, family history of
diabetes, and ethnicity (for total population). Model 2 adjusted for cohort, serum creatinine, alcohol
consumption, history of hypertension, family history of diabetes, fasting serum insulin, and ethnicity (for total
population).
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6 DISCUSSION
6.1 Study design and methodology
The strength of the MNCDS was that the sampling procedure, anthropometric
measurements, and laboratory tests followed the similar protocol in all cohorts. The
large random representative population sample covers 13 areas of Mauritius.
Considering the larger sample size drawn from large areas and the high participation
rate, the results may represent the characteristics of the general Mauritian Indian and
Mauritian  Creole  population.  A  representative  sample  of  the  general  population  was
selected using a stratified, random cluster sampling method in three urban districts and
four rural counties in Qingdao city. Considering the diversity in culture, diet, and
climate in China, however, the study result may not be representative of the general
Chinese population. More studies in other areas are required.
The large simple size enables a comprehensive data analysis by exclusion of subjects
with a personal history of hypertension, cardiovascular diseases including coronary
heart disease, stroke and peripheral vascular disease, renal failure, gout, and
individuals with diagnosed and undiagnosed diabetes at baseline. The serial
measurments of UA, FPG, 2-hPG, lipids and other covariates provides an opportunity
to study the trends and changes in the parameters of interest. The meansurement of the
75g 2-h OGTTs have been conducted for all eligible participants to define diabetes
status. Differences, however, exist in the laboratory measurements. To minimize the
discrepancy between study cohorts, we have tried to use sex- and cohort-specific SD
and Z scores for factors studied. In addition, a homogeneity test was performed to
check whether the effect sizes between cohorts differ, and the results showed that the
effect sizes of interest are quite homogenous between cohorts and therefore, we have
pooled the Mauritian cohorts together for certain data analyses to increase the power.
In our study, some potential confounding variables such as detailed dietary
information, detailed antihypertensive medication (especially thiazide diuretics,
beta-blockers), menstruation information at baseline, socioeconomic factors, C-
reactive protein, and urinary UA clearance were not available. To what extent these
factors may affect the results obtained was not explored.
Our study is the first prospective investigation of UA and the risk of incident diabetes
among  Mauritian  Indian  and  Mauritian  Creole  populations.  The  results  of  the  study
were consistent with the previous findings in other ethnic groups (Chien et al. 2008;
Meisinger et al. 2002; Perry et al. 1995). Nevertheless, since the re-examinations were
made in intervals and the exact date of a diagnosis of diabetes was not available, we
can not obtain the actual changes in blood UA concentration in relation to the onset of
diabetes  and  the  duration  of  diabetes.  This  is  also  the  first  detailed  report  on  the
association  of  the  serum  UA  with  the  FPG  and  2-hPG  in  the  Chinese  population  in
mainland China. The study is cross-sectional, however, and predictive value of the UA
in the development of future diabetes is not known.
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6.2 Interpretation of Findings
6.2.1 The high prevalence of hyperuricemia in Chinese populations
Our study revealed a higher prevalence of hyperuricemia in Qingdao compared to
those previously reported in mainland China, but the prevalence in this study was
lower than most of the reports from studies in Taiwan, and much lower than in
Taiwanese Aborigines (Chang et al. 2001; Chang et al. 1997; Chungtei 2003) (Table
1). The high UA levels in Taiwanese aborigines is due to the factors that they are
genetically more similar to the Malayo-Polynesians and have a higher BMI and
relatively higher amounts of alcohol consumption compared with non-aborigines
(Chang et al. 2001). In the past decades obesity and dyslipidemia have reportedly
increased in mainland China (Liu et al. 2004), which may to a large extent explain the
higher prevalence of hyperuricemia in our survey as compared to surveys made in
1990s. In addition, seafood is a major part of the food components in Qingdao. This
may also contributed to the high levels of UA observed in Qingdao.
6.2.2 Associations between high UA and metabolic risk factors
In  study  I,  the  associations  of  BMI  and  triglycerides  with  serum  UA  were  highly
significant for both sexes in general population in Qingdao, China. Serum UA was
demonstrated as significant in relation to hypertension, which was consistent with
findings  in  other  clinical  and  epidemiological  studies  (Conen et  al.  2004;  Fang et  al.
2000; Johnson et al. 2003; Li et al. 1997). Age appeared related to hyperuricemia in
women in our study, which was consistent with a report from a study in Beijing (Li et
al. 1997). In other Asian studies, age was also reported as being a risk factor for
hyperuricemia in women, but in men hyperuricemia has been found to decrease with
age (Chang et al. 2001; Nakanishi et al. 1999). The mechanisms relating hyperuricemia
to aging remains unclear. Estrogen may play a role in inducement increase UA
elimination (Nicholls et al. 1973; Yahyaoui et al. 2008). Alcohol consumption was
associated with hyperuricemia only in men in our study. This may be due to the fact
that women seldom drink alcohol in China.
In study II, high serum UA was significantly associated with several metabolic factors
such as a large waist circumference (or BMI), dyslipidemia, high BP, and both
individually and the clustering of these metabolic risk factors in the nondiabetic
population. These results were consistent with findings in the Japanese (Ishizaka et al.
2005; Nagahama et al. 2004b; Nakanishi et al. 2003), non-Hispanic Caucasians from
the US (Coutinho et al. 2007; Krishnan et al. 2007), and European people (Bonora et
al. 1998), despite different assays used for UA and different ethnic backgrounds. It was
recently reported that Korean men, age 30-39, with serum UA levels in the top
quintile, compared to the bottom quintile, had an approximately 1.6-fold increased risk
for metabolic syndrome (Ryu et al. 2007). Our study found an association of serum UA
with plasma glucose in the nondiabetic population, but these associations also
depended on the level of obesity and triglycerides as indicated by others (Chou et al.
2001; Johnson et al. 2003).
In obese individuals, high serum UA is due to an overproduction of UA and
impairment in renal clearance of UA owing to the influence of hyperinsulinemia
secondary to IR (Matsuura et al. 1998; Quinones Galvan et al. 1995; Yamashita et al.
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1986). The potential mechanisms relating hyperuricemia to fasting
hypertriglyceridemia are unknown. It has been speculated that it may be due to an
increase in NADPH requirement for de novo fatty acid synthesis. With increasing
NADPH, UA production is enhanced, and this may increase the serum UA level
(Vuorinen-Markkola et al. 1994). In addition, UA may play a role in the
pathophysiology of IR and cellular disturbances in glucose and lipid metabolism. UA
is also known to be an endogenous antioxidant and its efficacy in antioxidative
capacity in the early stages of the atherosclerotic process is strong (Nyyssonen et al.
1997). With advancing atherosclerosis, circulating UA levels increase and this previous
antioxidant paradoxically may become prooxidant (Hayden et al. 2004), contributing
to the pathogenesis of the metabolic syndrome (Sautin et al. 2007). In contrast, it has
also been reported that acute exposure to the high concentrations of UA did not impair
endothelial function in healthy men (Waring et al. 2004), suggesting that high UA may
not be a causal factor in vascular disease, but rather a marker of an existing problem.
6.2.3 UA was lower after diabetes developed
In the cross-sectional study (III) we found that serum UA increased with increasing
FPG levels up to the FPG level of 7.0 mmol/l, but decreased when FPG was over 7.0
mmol/l. An inverse relationship existed between 2-hPG and serum UA when 2-hPG
was  higher  than  8.0  mmol/l,  but  an  upward  increasing  trend  in  UA  levels  was  not
observed in the low 2-hPG range. These findings further confirmed previous findings
(Herman et al. 1976; Tuomilehto et al. 1988; Whitehead et al. 1992; Yano et al. 1977)
despite differences in assays used for UA and in diagnostic criteria for diabetes in
different studies. Furthermore, in the Mauritius longitudinal study (IV), UA levels
decreased from baseline levels in the same individuals who developed diabetes at the
end of the follow-up, except for menopausal women. After menopause the UA levels
increased (Nicholls et al. 1973), possibly compensating for the decrease in UA in
women who developed diabetes at the end of the follow-up.
Few studies have investigated the relationship between 2-hPG and UA due to the fact
that 2-h OGTT have not been widely applied. UA declined with increasing 2-hPG at
the upper range of the 2-hPG distribution, but did not find an increasing trend at the
lower 2-hPG range. Our study showed a stronger association between FPG and serum
UA than that for 2-hPG. The finding needs to be further examined. The physiological
bases of isolated IFG and isolated IGT are somewhat different (Davies et al. 2000;
DeFronzo 1999; Weyer et al. 1999). Although both isolated IFG and isolated IGT are
insulin-resistant states, they differ in their site of IR (Abdul-Ghani et al. 2006; Qiao et
al. 2003). People with isolated IFG predominantly have hepatic IR and normal muscle
insulin sensitivity, whereas individuals with isolated IGT have normal to slightly
reduced hepatic IR and moderate to severe muscle IR. Individuals with both IFG and
IGT manifest both muscle and hepatic IR. The pattern of insulin secretion also differs
between IFG and IGT (Nathan et al. 2007). People with isolated IFG have a decrease
in first-phase (0–10 min) insulin secretory response to intravenous glucose and a
reduced early-phase (first 30 min) insulin response to oral glucose. The late-phase (60–
120 min) plasma insulin response during the OGTT, however, is normal in isolated
IFG. Isolated IGT also has a defect in early-phase insulin secretion in response to an
oral glucose load and in addition has a severe deficit in late-phase insulin secretion.
Therefore, the extent of which the difference in glucose regulations at fasting and
postprandial conditions has contributed to the observed relationship between UA and
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glucose levels requires further investigation.
Studies have revealed that insulin can enhance renal proximal tubular UA reabsorption
in humans, linking to the tubular reabsorption of sodium (Cappuccio et al. 1993;
Muscelli et al. 1996; Quinones Galvan et al. 1995). In addition, IR increases serum UA
through the hexose monophosphate shunt connecting with UA production (Fox 1981;
Modan et al. 1987). Thus, high insulin levels can lead to hyperuricemia. In our study,
the high fasting insulin levels may explain the high baseline UA levels in individuals
with diabetes at follow-up, but can not explain the decrease in UA levels after the onset
of diabetes. The reduction in UA levels after the onset of diabetes may be a
consequence of the excess excretion of UA due to the hyperosmotic effect caused by
high blood glucose concentration and glycosuria (Cook et al. 1986).
6.2.4 High UA at baseline predicted incident diabetes in Mauritian Indian and
Creole
In the population-based longitudinal study from Mauritius (IV), baseline UA, after
multivariate adjustments, independently predicted the development of diabetes in
Mauritian  men,  but  not  in  Mauritian  women.  Aging  and  sex  hormones  (estrogen  and
androgen) may contribute to gender difference, but the mechanism is uncertain. In
addition, the difference in smoking and diet between men and women may be involve,
since smoking and drinking alcohol were more popular for men than women in
Mauritius. This can not be investigated, however, because the detailed dieting
information (e.g. meat and seafood) was not collected. A previous study reported a
direct  and  graded  relationship  between  UA  and  the  risk  of  diabetes  in  the  Mauritian
population over 5 years (Boyko et al. 2000), and our findings confirm it in a more
detailed analysis of data collected over a maximum of 11 years of follow-up.
UA may play a direct role in the pathogenesis of diabetes by the possible inhibition of
endothelial function (Nakagawa et al. 2006), inhibition of nitric oxide bioavailability
(Baldus et al. 2005) and stimulation of vascular smooth muscle cell proliferation (Price
et al. 2006). Furthermore, deficiency of endothelial-derived nitric oxide is believed to
be the primary defect that links IR and cellular disturbances in glucose and lipid
metabolism (Cersosimo et al. 2006). The underlying mechanism of UA in the process
of deterioration of glucose metabolism is still not clear, and needs to be further
investigated.
6.3 Implications for further research and clinical management
We found serum UA levels clearly strongly associated with metabolic risk factors,
tended to increase with increasing FPG concentration in nondiabetic individuals, but
decreased in diabetic individuals. Moreover, high baseline UA concentrations
predicted the development of diabetes in Mauritian Indian and Creole. Nonetheless,
the prognostic value of UA in the development of type 2 diabetes is not clear, and the
direction of causality between hyperuricemia and metabolic disorders is uncertain.
Although prospective cohort studies are useful in establishing temporal relationship
between exposure and a discrete disease endpoint, the direction of the association
between hyperuricemia and metabolic disorders is more difficult to ascertain because
all those variables are continuous and correlated with each other. Further studies to
investigate the pathophysiological mechanism underlying the relationship between
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glucose and UA, and between metabolic syndrome and UA, may help to understand
the  formation  of  these  metabolic  disorders  and  find  a  way  to  stop  or  delay  the
development of diabetes and cardiovascular diseases.
Regardless of the pathophysiological explanations, these observations raise an
important  clinical  question.  Is  it  possible  to  prevent/postpone  the  onset  of  type  2
diabetes by reducing serum UA in people with pre-diabetes? Recently, in a short-term,
crossover designed clinical trail of adolescents with newly diagnosed hypertension,
treatment with allopurinol resulted in reduction of BP (Feig et al. 2008). The results
represent a new potential therapeutic approach, although not a fully developed
therapeutic strategy due to potential adverse effects. These preliminary findings require
confirmation in larger randomized, controlled clinical trails. Allopurinol and other
agents of febuxostat, or pegylated, would be potential candidate drugs for intervention,
but the safety and cost-effectiveness of these medications in pre-diabetes individuals
first need to be studied.
It would be important to advise subjects with hyperuricemia and gout to control or loss
weight,  to  increase  physical  activity,  and  to  follow  healthy  dietary  recommendations
(Hak et al. 2008), in order to reduce the risk of type 2 diabetes and metabolic
syndrome, and improve overall long-term outcomes.
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7 CONCLUSIONS
The conclusions related to the specific objectives are:
1. The prevalence of hyperuricemia was high in the urban Chinese
populations in Qingdao. Obesity, dyslipidemia, and hypertension were
important risk factors related to the hyperuricemia.
2. Blood  UA  was  associated  with  the  clustering  of  metabolic  risk  factors  in
nondiabetic populations of Mauritian Indian, Mauritian Creole, and Chinese
living in Qingdao. Whether including UA in the definition of the metabolic
syndrome would improve the ability of the metabolic syndrome to predict
cardiovascular disease and diabetes needs further investigation.
3. Serum UA levels tended to increase with increasing FPG concentrations in
nondiabetic individuals, but decreased in diabetic individuals. The
relationship between UA and 2-hPG levels was not as strong as that for
FPG. It would be interesting to explore to the extent of which the difference
in glucose regulations at fasting and postprandial conditions has contributed
to the observed relationship.
4. A high baseline UA level predicted the development of future diabetes,
independently of major confounding or mediating risk factors in Mauritian
in men, but not in Mauritian women. The clinical use of UA as a marker of
glucose and other metabolic risk factors needs to be further studied.
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